Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE  
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË  
 
Tel: +32 229 -91111. Fax: +32 229 -64301. E -mail: COMP -MERGER -REGISTRY@ec.europa.eu .  EUROPEAN COMMISSION  
Brussels,  22.10.2021  
C(2021 ) 7708  final 
PUBLIC VERSION  
 
CVC Capital Partners SICAV -FIS S.A.  
20 Avenue Monterey  
L-2163 Luxembourg  
Luxembourg  
Subject : Case M.  10247 – CVC/Cooper  
Commission decision pursuant to Article 6(1)(b) of Council Regulation 
No 139/20041 and Article 57 of the Agreement on the European Economic 
Area2 
Dear Sir or Madam,  
(1) On 17 September 2021, the Commission received notification of a proposed 
concentration pursuant to Article 4 of the Merg er Regulation , by which CVC 
Capital Partners SICAV -FIS S.A. (“CVC”, Luxembourg or the “Notifying Party”) 
acquire s within the meaning of Article 3(1)(b) of the Merger Regulation sole control 
of the whole of Cooper Consumer Health S.A.S. and its subsidiaries (“Cooper”, 
France or the “Target”) (the “Transaction”)3, by way of purchase of securities. 
Together, CVC and Cooper are referred to as the “Parties”.  
                                                 
1  OJ L 24, 29.1.2004, p. 1 (the ’Merger Regulation ’). With effect from 1 December 2009,  the Treaty on the 
Functioning of the European Union ( ‘TFEU ’) has introd uced certain changes, such as the replacement of  
‘Community ’ by ‘Union ’ and ‘common market ’ by ‘internal market ’. The terminology of the TFEU will 
be used throughout this decision.  
2  OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).  
3  Publication in the Offi cial Journal of the European Union No C 392 , 28.09.2021, p. 5.  
In the published version of this decision, 
some information has been omitted 
pursuant to Article 17(2) of Council 
Regulation (EC) No 139/2004 concerning 
non-disclosure of business secrets and other  
confidential information. The omissions are 
shown thus […] . Where possible the 
information omitted has been replaced by 
ranges of figures or a general description.  
 
2 1. THE PARTIES  
(2) CVC  and/or its subsidiaries manage investment funds and platforms. CVC controls a  
number of companies, including companies in the pharmaceutical sector, e.g., 
Recordati; Genetic; and Theramex, as well as in the private hospital and clinics 
(Hellenic health Care Group and Mehiläinen ), nursing homes (Vitalia), provision of 
specialised me dical equipment (Sebia), flexible packaging (AR Packaging) and 
packaging machinery (Syntegon) sectors.  
(3) Cooper  and its subsidiaries develop, produce, and market pharmaceuticals, which are 
typically sold over the counter (“OTC”).  
2. THE OPERATION AND THE CONC ENTRATION  
(4) Pursuant to a Put Option Agreement, dated 10 March 2021, and a Securities 
Purchase Agreement, dated 5 May 2021, CVC plans to acquire control over Cooper 
through a special purpose vehicle. P ost-Transaction, CVC will hold [60-70]%  of the 
Target’s s hare capital. As a result, CVC will acquire sole control over Cooper. The 
Transaction constitutes a concentration under Article 3(1)(b) EUMR.  
3. UNION DIMENSION  
(5) The undertakings concerned have a combined aggregate world -wide turnover of 
more than EUR 5 000 m illion4. Each of them has a Union -wide turnover in excess of 
EUR 250 million, but they do not achieve more than two -thirds of their aggregate 
Union -wide turnover within one and the same Member State. The notified operation 
therefore has a Union dimension.  
4. ASSESSMENT  
4.1. Horizontal overlaps  
(6) Both Parties are active in the development, manufacture, and commercialisation of 
finishe d dose pharmaceuticals (“FDPs”) . FDPs are pharmaceutical products that 
have undergone all stages of production, including packaging in  the final container 
and labelling.  
4.1.1.  Market Definitions   
4.1.1.1.  Product market definitions  
(7) To define relevant product markets regarding FDPs, the Commission typically takes 
into account the Anatomical Therapeutic Classification (“ATC”) of the European 
Pharmaceutical Marketing Research Association. In the context of this classification, 
at the ATC3 level,5 FDPs are grouped by therapeutic indications. The Commission 
                                                 
4  Turnover calculated in accordance with Article 5 of the Merger Regulation.  
5  ATC3 level classification is narrower than ATC1 and ATC2 level classifications. At ATC1, drugs are 
divided into 16 anatomical main groups. At ATC2, drugs are divided at pharmacological or therapeutic 
groups.  
 
3 uses ATC3 as the starting point for relevant product market definition, since all 
products  in the same ATC3 class generally have the same therapeutic indication and 
cannot be substituted by products from other ATC3 classes.6 However, the 
Commission also recogni sed7 that it may be appropriate to carry out analyses at the 
narrower classification level ATC4,8 or possibly at the level of molecule. ATC 
classification concerns prescription -bound (Rx) and OTC -sold drugs. For OTC -sold 
drugs, I QVIA9 also administers the Consumer Health Classification (“CHC”). With 
respect to OTC -sold drugs, the Commissio n typically uses CHC3 level10 (the 
equivalent of ATC3) as a starting point for relevant product market definition but 
narrower delineations are also considered (e.g., at CHC4 level (the equivalent of 
ATC4) or by molecule).11 
(8) For the purposes of the present D ecision , it is not necessary to depart from the above 
approach , that is to define the markets for FDPs either at ATC3/CHC3, ATC4/CHC4 
or molecule levels. The market investigation did not provide any indications that 
would require the Commission to depart f rom its previous decisional practice with 
respect to the product market definition for FDPs concerning the FDP categories in 
which the Parties overlap.  
(A) Methodology for the identification and the assessment of affected 
markets  
(9) To identify the affected marke ts that the Transaction gives rise to in relation to 
FDPs, the Notifying Party used IQVIA data (previously known as IMS). These are 
data on sales in value and volume of FDPs compiled by IQVIA, a third -party 
intelligence provider focusing on the healthcare sector.   
(10) As will be further discussed further below in the present Decision  (paragraphs (41) 
to (43), the Commission consistently defines relevant markets at national level.  
(11) In line with Commission precedents in pharmaceutical mergers with a large number 
of affected markets (involving numerous product and geographic markets), the 
Commission has applied a system of filters aimed at determining the group of 
markets where concerns are  most likely and on which it focuses its analysis. Based 
on the Commission’s decisional practice  in the pharmaceutical sector,12 horizontally 
affected markets regarding FDPs can be grouped in the categories summarized in  
  
                                                 
6  Case M.9995 – Permira/Neuraxpharm, para. 7.  
7  Case M.9995 – Permira/Neuraxpharm, para. 7. 
8  ATC4 level classification is typically based on mode of action or mode of administration of the drugs.  
9  IQVIA is an American multinational company serving the combined industries of health information 
technology and clinical research, formerly Quintiles  and IMS Health, Inc.  
10  Case COMP/M.8889 – Teva/PGT OTC Assets , para. 21  
11  Case COMP/M.8889 – Teva/PGT OTC Assets , para. 21 
12  Case M.9554 – Elanco Animal Health/Bayer Animal Health Division, para. 89; M.8889 - Teva/PGT OTC 
Assets, para. 35; M.7746 – Teva/Allergan Generics, para. 58; and M.9044 - CVC/Recordati, para. 25; 
M.7645 - Mylan/ Perrigo, para. 33; M.8974 – Procter & Gamble / Merck Consumer Health Business, para. 
24. 


 
6 etc. for the treatment o f haemorrhoids and anal fissures.14 Preparations used for 
treatment of perineal trauma are also classified here.  
(16) The Commission has in the past left open the questions of either whether ATC3 class 
was the appropriate level  to define the relevant product mar ket for antihaemorrhoids 
(as opposed to the ATC4 class)15, or whether prescription and non prescription - 
products should be seen as belonging to the same market. 16 The Commission has not 
assessed antihaemorrhoids in the past based on their CHC3 or CHC4 clas sification.  
(17) As explained above,17 the Commission consistently defines the market for FDPs 
looking at both the ATC3/CHC3 level and at ATC4/CHC4 level. Also in this case, 
both ATC3 class C5A, CHC3 code 10A1 and CHC4 code 10A1O constitute 
plausible relevant pr oduct markets.  
(18) In the present case, the Notifying Party considers that the precise product market 
definition can be left open because the Transaction does not give rise to competition 
concerns under any plausible product market definition (including under the 
narrowest plausible market definition where the Parties’ activities overlap, namely at 
CHC4 level – Antihaemorrhoids – Ointments / Creams).  
(19) The Commission’s market investigation did not provide conclusive evidence 
regarding the question whether the rel evant product market should be defined at 
ATC3/CHC3 level (including all types of antihaemorrhoids) or at ATC4/CHC4 level 
(including only antihaemorrhoidal ointments and creams).18 For the purposes of this 
decision, the product market definition for antihae morrhoids can be left open, as the 
Transaction does not give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement even in the narrowest 
plausible market where the Parties’ activities overlap (i.e.,  antihaemorrhoidal 
ointments and creams at CHC4 level).  
(C.ii)  Sore throat remedies  
(20) In the past, 19 the Commission considered a relevant market for sore throat remedies 
at ATC3 level (R2A) but eventually left open the issue of product market definition. 
The Commi ssion has not assessed sore throat remedies in the past based on their 
CHC3 or CHC4 classification.  
(21) In the present case, the Notifying Party considers that the precise product market 
definition could be left open because the Transaction does not give rise  to 
competition concerns under any plausible product market definition (including under 
the narrowest plausible market definition where the Parties’ activities overlap, 
namely at CHC4 level – sore throat remedies in the form of aerosols and sprays).  
                                                 
14  Although the ATC3 class C5A (topical antihaemorrhoidals) is not fully identical to the CHC3 class 10A1 
(antihaemorrhoids) since the ATC3 class only covers the topical drugs against haemorrhoids, both classes 
have essentially the same therapeutic indicatio n: the treatment of haemorrhoids. Consequently, ATC3 
class C5A includes some, but not all, products of the Parties falling under the CHC3 class 10A1 in Italy.  
15  See M.4198 – Bayer / Schering, paragraph 12.  
16  Commission decision, Case M.4314 – Johnson & J ohnson / Pfizer Consumer Healthcare, paragraph 22.  
17  See paragraph (7). 
18  Replies to Questionnaire Q3 and to Questionnaire Q4.  
19  M.7276 GSK / Novartis, paragraph 249.  
 
7 (22) The Co mmission’s market investigation did not provide conclusive evidence 
regarding the question whether the relevant product market should be defined at 
ATC3/CHC3 level (including all types of sore throat remedies) or at ATC4/CHC4 
level (including only aerosols  and sprays).20 For the purposes of this decision, the 
product market definition for sore throat remedies can be left open, as the 
Transaction does not give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EE A agreement even in the narrowest 
plausible market where the Parties’ activities overlap (i.e., sore throat remedies in 
form of aerosols or sprays at CHC4 level).  
(C.iii)  Mouth pain relief products  
(23) In the past, 21 the Commission considered that the there are two s eparate product 
markets for mouth pain relief products. Namely (i) a market for adult mouth pain 
relief products that covers products classified under ATC4 class A1A2 excluding 
mouthwashes (i.e. antiseptics and anti -infectives) and products classified unde r 
ATC4 class A1A3 (i.e. anti -inflammatories and analgesics), and (ii) a market for 
paediatric mouth pain relief products that covers products classified under ATC4 
class A1A2 excluding mouthwashes (i.e. antiseptics and anti -infectives) and 
products classif ied under ATC4 class A1A3 (i.e. anti -inflammatories and 
analgesics).  
(24) The Commission has not assessed mouth pain relief products in the past based on 
their CHC3 or CHC4 classification.  
(25) The Notifying Party does not contest the Commission’s general approach to the 
product market definition for FDPs. However, it submits that in markets where the 
Parties’ activities overlap, the competition takes place at ATC3 level.22  
(26) The Commission’s market investigation did not provide any indication on whether 
the relevant product market should be defined at ATC3/CHC3 level (including all 
types of mouth pain relief products) or at ATC4/CHC4 level (including only 
liquids). For the purposes of this decision, the product market definition for mouth 
pain relief products can be l eft open, as the Transaction does not give rise to serious 
doubts as to its compatibility with the internal market or the functioning of the EEA 
agreement even in the narrowest plausible market where the Parties’ activities 
overlap (i.e., mouth pain relief  in the form of liquids at CHC4 level).  
(C.iv)  Ear care products  
(27) The Parties’ ear care products that give rise to affected markets belong to the CHC3 
code 08A1 – Ear Care and CHC4 code 08A1Z – Ear Care in other forms. The 
Commission has not previously considered  the markets for ear care products 
belonging to these categories. As explained above,23 the Commission consistently 
defines market for FDPs based on both the CHC3 level and at CHC4 level, and 
therefore both CHC3 code 08A1 and CHC4 code 08A1Z constitute plau sible 
relevant product markets.  
                                                 
20  Replies to Questionnaire Q1, question 11.  
21  Case M.5953 – Reckitt Benckiser/SSL , paragraph 27.  
22  Form CO, paragraph 99.  
23  See paragraph (7). 
 
8 (28) The CHC4 code 08A1Z, however, is a catch -all category that includes any products 
that cannot be included in other CHC4 codes within the CHC3 code 08A1, instead of 
combining products with similar properties. With respect to o ther catch -all 
pharmaceutical classes, the Commission has previously considered that these do not 
form an appropriate basis for defining the relevant product markets.24 
(29) The Notifying Party does not contest the Commission’s general approach to the 
product market definition for FDPs. However, it submits that in markets where the 
Parties’ activities overlap, the competition takes place at ATC3 level.25 With respect 
to CHC4 code 08A1Z specifically, the Notifying Party notes that the category does 
not represent the actual market conditions given its catch -all nature.26  
(30) The investigation did not provide any indication on whether CHC4 code 08A1Z – 
Ear Care in other forms could constitute a separate relevant product market.  
(31) For the purposes of this decision, the exa ct product market definition for ear care 
products can be left open since the Transaction does not give rise to serious doubts 
as to its compatibility with the internal market or the functioning of the EEA 
agreement even under the narrowest plausible marke t defined at the CHC4 code 
08A1Z –Ear Care products in other forms.  
(C.v) Antitussives (in combination)  
(32) ATC4 class R5D2 includes antitussives (which relieve coughs by blocking the cough 
reflex, and are most effective at relieving dry coughs, also known as cough  
suppressants) in combinations with expectorants, antihistamines, ephedrine, herbal 
tinctures, etc. 27 ATC3 class R5D includes all antitussives.  
(33) The Commission has not previously considered the markets for antitussives 
belonging to these categories. As expl ained above,28 the Commission consistently 
defines market for FDPs based on both the ATC3 level and at ATC4 level, and 
therefore both ATC3 code R5D and ATC4 code R5D2 constitute plausible relevant 
product markets.  
(34) The investigation did not provide any indic ation on whether the relevant product 
market could be defined either at ATC3 class R5D or ATC4 class R5D2.  
(35) In the present case, the Notifying Party considers that the precise product market 
definition for antitussives could be left open because the Transac tion does not give 
rise to competition concerns under any plausible product market definition (namely 
the narrowest plausible market definition where the Parties’ activities overlap, ATC4 
class R5D2).  
                                                 
24  Case M.5476 – Pfizer/Wyeth, paragraph 43.  
25  Form CO, paragraph 99.  
26  Form CO, paragraph 386.  
27  Combinations with analgesics and antipyretics (ATC3 class R5A) and combinations with anti -infectives 
(ATC3 class R5B) are excluded.  
28  See paragraph (7). 
 
9 (C.vi)  Intestinal anti -infective anti -diarrhoeals  
(36) Intestinal anti-infective anti -diarrhoeals are used for disinfection and stabilisation of 
the intestinal microflora and for treatment of acute diarrhoeal diseases. They can be 
based on different molecules, including nifuroxazide, colistin, fidacomicin, and 
rifaximin.  
(37) In Sanofi -Aventis/Zentiva , the Commission considered a relevant market for 
intestinal anti -infective anti -diarrhoeals at ATC3 level (A7A) but eventually left 
open the issue of relevant market definition.29 The Commission has not assessed 
intestinal anti -infective anti -diarrhoeals at molecule level in the past.  
(38) In the present case, the Notifying Party considers that the precise product market 
definition could be left open because the Transaction does not give rise to 
competition concerns under any plausible  product market definition (including under 
the narrowest plausible market definition where the Parties’ activities overlap, 
namely at molecule level – nifuroxazide -based intestinal anti -infective anti -
diarrhoeals).  
(39) The investigation did not provide any i ndication on whether the ATC3 class A7A 
could be considered a distinct product market.   
(40) For the purposes of this decision, the product market definition for intestinal anti -
infective anti -diarrhoeals can be left open, as the Transaction does not give rise to 
serious doubts as to its compatibility with the internal market or the functioning of 
the EEA agreement even in the narrowest plausible market where the Parties’ 
activities overlap (i.e., at molecule level for nifuroxazide -based products).  
4.1.1.2.  Geographic m arket definitions  
(41) For FDPs, the Commission consistently defines relevant markets at national level.30 
(42) The market investigation did not provide any indications that would require the 
Commission to depart from its previous decisional practice on the geographic scope 
of the different plausible markets for FDPs. 31 
(43) Therefore, for the purposes of this decision, the Commission considers the 
geographic scope of the different plausible markets for FDPs, including all of the 
Group1/1+ markets, Group 2 and Gro up 3 to be national in scope.  
4.1.2.  Legal framework  
(44) Article 2 of the Merger Regulation requires the Commission to examine whether 
notified concentrations are compatible with the internal market, by assessing whether 
they would significantly impede effective comp etition in the internal market or in a 
substantial part of it, in particular as a result of the creation or strengthening of a 
dominant position.  
                                                 
29  Case M.5253 – Sanofi -Aventis/Zentiva , recitals 55ff.  
30  Case M.9995 – Permira/Neuraxpharm , para. 11.  
31  Replies to Questionnaires Q1 to Questionnaire Q6.  
 
10 (45) A merger giving rise to a significant impediment of effective competition may do so 
as a result of the creati on or strengthening of a dominant position in the relevant 
market(s). Moreover, mergers in oligopolistic markets involving the elimination of 
the important competitive constraints that the parties previously exerted on each 
other, together with a reduction  of competitive pressure on the remaining 
competitors, may also result in a significant impediment to effective competition, 
even in the absence of dominance.  
(46) The Commission Guidelines on the assessment of horizontal mergers under the 
Merger Regulation (th e “Horizontal Merger Guidelines”)32 describe horizontal non -
coordinated effects as follows: “A merger may significantly impede effective 
competition in a market by removing important competitive constraints on one or 
more sellers who consequently have incre ased market power. The most direct effect 
of the merger will be the loss of competition between the merging firms. For 
example, if prior to the merger one of the merging firms had raised its price, it 
would have lost some sales to the other merging firm. T he merger removes this 
particular constraint. Non -merging firms in the same market can also benefit from 
the reduction of competitive pressure that results from the merger, since the merging 
firms’ price increase may switch some demand to the rival firms, which, in turn, may 
find it profitable to increase their prices. The reduction in these competitive 
constraints could lead to significant price increases in the relevant market.”33  
(47) The Horizontal Merger Guidelines list a number of factors which may influen ce 
whether or not significant non -coordinated effects are likely to result from a merger, 
such as large market shares of the merging firms, the fact that the merging firms are 
close competitors, the limited possibilities for customers to switch suppliers, or the 
fact that the merger would eliminate an important competitive force.34 That list of 
factors applies equally regardless of whether a merger would create or strengthen a 
dominant position, or would otherwise significantly impede effective competition 
due to non -coordinated effects. Furthermore, not all of these factors need to be 
present for significant non -coordinated effects to be likely. The list of factors, each 
of which is not necessarily decisive in its own right, is also not an exhaustive list.35  
(48) Finally, the Horizontal Merger Guidelines describe a number of factors, which could 
counteract the harmful effects of the merger on competition, including the likelihood 
of buyer power, the entry of new competitors on the market, and efficiencies.  
4.1.3.  Competi tive assessment of group 2 and 3 markets  
(49) For all of the Group 2 and Group 3 markets, the market shares of the Parties are 
limited, and significant competitors that will likely sufficiently constrain the merged 
entity remain on the market post -Transaction a nd/or the Transaction brings about 
only a limited increment. In addition, the market investigation did not reveal any 
concerns in relation to any of the Group 2 and 3 markets.36  
                                                 
32  OJ C 31, 5.2.2004, p. 5. 
33  Horizontal Merger Guidelines, paragraph 24.  
34  Horizontal Merger Guidelines, paragraphs 27 and following.  
35  Horizontal Merger Guidelines, paragraphs 24 -38. 
36  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
 
11 (50) The Commission assessed the competitive situation on these markets analysing the 
nature and the number of existing competitors and considered that the Transaction 
does not raise serious doubts as to its compatibility with the internal market or the 
functio ning of the EEA agreement as a result of a horizontal effects in any of those 
markets. Consequently, in line with previous decisions37 Group 2 and Group 3 
overlaps will not be assessed any further in the present Decision.  
4.1.4.  Competitive assessment of group 1 and 1+ markets  
4.1.4.1.  Antihaemorrhoids in Italy and in Romania  
(51) At each of the ATC3 class C5A (topical antihaemorrhoidals) and CHC3 code 10A1 
(antihaemorrhoids), the Parties activities result in a Group 1/1+ affected market in 
Italy, while in the CHC4 code 10A1O ( antihaemorrhoids - ointments and creams) 
the Parties activities result in a Group 1/1+ affected market in Italy and Romania.  
(A) ATC3 level C5A (topical antihaemorrhoidals) in Italy  
(52) Recordati sells Proctolyn (based on fluocinolone acetonide and ketocaine), whi le 
Cooper sells Ruscoroid (based on ruscogenins and tetracaine) in Italy.  
(53) The Notifying Party submits that the Transaction does not give rise to competition 
concerns in topical antihaemorrhoidals in Italy, because the Parties’ products do not 
compete close ly, given their different active ingredients  and the combined entity 
would face vigorous competition in this market.  
(54) Tables 4 below show the market shares of the Parties and their main rivals in the 
market for topical antihaemorrhoidals in Italy in the la st three years, in value and in 
volume.  
  
                                                 
37  See M.8974 – Procter & Gamble / Merck Consumer Health Business , para . 25. 

 
13 (55) In 2020, the combined share of the Parties in the market for topical 
antihaemorrhoidals in Italy was [40-50]%  in value and [40-50]%  in volume (with an 
increment of [5-10]%  in value and [5-10]%  in volume contributed by Cooper). There 
are four competitors wi th market shares in value and volume  higher than the 
increment brought by the Transaction.  
(56) In this market, the Transaction is unlikely to give rise to serious doubts as to its 
compatibility with the internal market or the functioning of the EEA agreement for 
the following reasons:  
(a) Post-Transaction, in the market for topical antihaemorrhoidals in Italy, the 
combined entity would face competitive constraints from several rivals. 
According to IQVIA, in 2020, there were around 12 competitors active in this 
mark et.38 These rivals include Bayer, Neopharmed Gentili, Glaxosmithkline and 
Alfasigma, each holding shares at, or above 10% (both in value and in volume) 
in 2020. The results of the market investigation confirm this. All respondents 
(competitors and customers ) replied that post -Transaction a sufficient number of 
suppliers will continue offering topical antihaemorrhoidals in Italy .39  
(b) There is no evidence that the products of the Parties in this market compete 
closely with each other, since they are not close su bstitutes. Proctolyn and 
Ruscoroid are based on different active ingredients and Proctolyn contains 
corticosteroids, while Ruscoroid does not. Products with corticosteroids may lead 
to severe side effects, consequently, anti -haemorrhoidals with corticoster oids are 
preferably used to treat acute and severe haemorroids due to a strong anti -
inflammatory action for a short period of no longer than seven days, while anti -
haemorroidals without corticosteroids can be used for milder symptoms and 
possibly for a lon ger period as a maintenance therapy since they have a weaker 
anti-inflammatory action.40 The results of the market investigation confirmed to a 
certain extent that Proctolyn and Ruscoroid are not each others’ closest 
competitor. 41 
(c) Finally, the market investigation did not reveal any concerns in relation to 
topical antihaemorrhoidals in Italy.42  
(57) In light of the above considerations, the Commission concludes that the Transaction 
does not raise serious doubts as to its compatibility with the internal mark et or the 
functioning of the EEA agreement as a result of a horizontal effects in the market for 
topical antihaemorrhoidals in Italy . 
                                                 
38   See Form CO Annex 7.4 -1. 
39   Replies to Questionnaire Q3, question 12 - 14 and Questionnaire Q4, question 9 - 11.  
40  Replies to Questionnaire Q3, question 10 and Questionnaire Q4, question7.  
41  Replies to Questionnaire Q3, q uestion 8 and Questionnaire Q4, question 6.  
42  Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised 
competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only 
one competitor of the Parties considered that the Transaction could have a negative impact because of the 
increased capacity of the merged entity to invest. However, this customer does not foresee any impact on 
the price and availability of topical antihaemo rrhoidals in Italy.  
 
14 (B) CHC3 code 10A1 (antihaemorrhoids) and CHC4 code 10A1O 
(antihaemorrhoids - ointments and creams) in Italy  
(58) Recordati sells P roctolyn in the forms of cream and suppositories, and Proctolyn 
Integra Plus, a food supplement sold in the form of sachets. Cooper sells Ruscoroid 
in the form of cream, Ruscoroid Forte, a food supplement in sachet form, Vasostar, 
which comes in the form o f a cream and used to treat internal and external 
haemorrhoids and Micro H in the form of a gel or wipes, producing a calming effect 
that reduces haemorrhoidal problems.43 
(59) While the products contain some of the  same active substances, each product also 
contain further substances with different mechanisms of action to achieve the desired 
effect.44 
(60) The Notifying Party submits that the Transaction does not give rise to competition 
concerns either in antihaemorrhoids, or in antihaemorrhoidal ointments and creams 
in Italy, because the Parties’ products do not compete closely, given their different 
active ingredients  and the combined entity would face vigorous competition in this 
market.  
(61) Tables 6 and 7 below show the market shares of the Parties and their main riva ls in 
the market for antihaemorrhoids in Italy in the last three years in value and in 
volume.  
  
                                                 
43  Micro H is exiting the market as a result of commercial decisions by Cooper. See Form CO, paragraph 
281. 
44  See Form CO, paragraph 289.  




 
19 exist in different forms, cream (Pro ctolyn, Vasostar and Ruscoroid), food 
supplements in the form of a sachet (Proctolyn Integra Plus and Ruscoroid Fort) 
and single -dose gel and a single -dose wipe (Micro H). The results of the market 
investigation confirmed to a certain extent that the Parti es’ products are not each 
others’ closest competitor. 51 
(c) Finally, the market investigation did not reveal any concerns in relation to 
antihaemorrhoids and antihaemorrhoidal creams and ointments in Italy.52  
(66) In light of the above considerations, the Commission concludes that the Transaction 
does not raise serious doubts as to its compatibility with the internal market or the 
functioning of the EEA agreement  as a result of a horizontal effects  in the markets 
for antihaemorrhoids and in the market for  antihaemorrhoidal creams and ointments 
in Italy .  
(C) CHC4 level 10A1O (antihaemorrhoids - ointments and creams) in 
Romania53 
(67) Recordati sells Procto Glyvenol in the form of an ointment. Cooper has sold its 
Micro H (in fo rm of a gel) in an one -off sale.54  
(68) The Notifying Party submits that the Transaction does not give rise to competition 
concerns in antihaemorrhoidal ointments and creams in Romania, because the 
Parties’ products do not compete closely, given their different  active ingredients  and 
the combined entity would face vigorous competition in this market.  
(69) Tables 10 and 11 below show the market shares of the Parties and their main rivals 
in the market for antihaemorrhoids - ointments and creams in Romania in the last  
three years, in value and in volume.  
  
                                                 
51  Replies to Questionnaire Q3, question 8 and Questi onnaire Q4, question 6.  
52  Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised 
competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only 
one competitor of the Parties considered that the Transaction could have a negative impact because of the 
increased capacity of the merged entity to invest. However this customer does not foresee any impact on 
the price and availability of topical antihaemorrhoidals in Italy.  
53  At ATC3/CHC3 level (10A1), the Parties’ market shares result in a Group 3 affected market  in Romania . 
54  The Notifying Party submits that this was truly marginal in absolute terms ([…]). See Form CO, 
paragraph 318. Moreover, the Notifying Party recalls that Micro H is exiting the market, see footnote 43.  



 
23 (with an increment of [10-20]%  contributed by Cooper).63 In this market, the 
Transaction is unlikely to give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement for the following reasons:  
(a) Post-Transaction, in the market for sore throat remedies in the form of 
aerosols/sprays in France, the combined entity would face competitive 
constraints from several rivals. According to IQVIA, in 2020, there were more 
than 60 competitors active in this market. These rivals include Procter & 
Gamble; Urgo; and Pfizer, each holding shares above 5% in 2020. The results of 
the market investigation confirm this. All respondents (competitors and 
customers) replied that post -Transaction a sufficient number of suppliers will 
continue offering sore throat remedies in the form o f aerosols  and sprays in 
France.64  
 
(b) There is no evidence that the products of the Parties in this market compete 
closely with each other. Colludol and Hexaspray have different therapeutic 
effects.65 Hexaspray has antibacterial and antiseptic action. Colludo l has 
antiseptic action but also includes lidocaine and thus works as an anaesthetic for 
the sore throat. Colludol competes more closely with Procter & Gamble’s and 
Urgo’s products (which contain lidocaine and have anaesthetic action) than with 
Hexaspray.  
 
The results of the market investigation confirm this. None of the respondents 
(competitors and customers) identified Hexaspray as the closest competing 
product for Colludol.66 The vast majority of the respondents did not identify 
Hexaspray among the three closest competitors to Colludol nor Colludol among 
the three closest competitors to Hexaspray.67  
 
[…].68 […].69 […].70 
 
(c) Sore throat remedies are also available in forms other tha n aerosols/sprays, 
e.g., as lozenges or syrups. While lozenges and syrups are not part of the 
relevant market which is affected by the concentration (01C1A – Sore throat 
Remedies – Aerosols/Sprays), they could still exert competitive constraints 
over the c ombined entity post -Transaction.  
 
The results of the market investigation confirm this. The majority of 
competitors stated that consumers consider substitutable (at least to some 
                                                 
63  By volume, Cooper held a share of [0 -5]% and CVC held a share of [0 -5]%. This discrepancy between 
value - and volume -based market shares exists becaus e IQVIA does not properly convert “actual units” of 
competitor products to “standard units” (which it does for the Parties’ products).  
64  Replies to Questionnaire Q1, question 12 and Questionnaire Q2, question 10.  
65  Clariver and Hexaspray also do not co mpete closely. Clariver is based on natural ingredients while 
Hexaspray includes active pharmaceutical ingredients. In the market investigation, none of the 
respondents identified Clariver as a product competing closely with Hexaspray (Replies to Questionn aire 
Q1, question 8 and Replies to Questionnaire Q2, question 6).  
66  Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.  
67  Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.  
68  Form CO, Annex 7.4 -XI – Target’s  Document (Part 1) on Colludol_Hexaspray, page 30.  
69  Form CO, Annex 7.4 -XI – Target’s Document (Part 1) on Colludol_Hexaspray, page 30.  
70  Form CO, footnote 161.  
 
24 extent) sore throat remedies in aerosols/sprays and sore throat remedies in 
other forms.71  
 
In its internal documents, Recordati […]”.72  
 
(d) The market investigation did not reveal any substantiated concerns in relation 
to sore throat remedies in the form of aerosols/sprays in France.73  
(77) In light of the above considerations, the Commission concludes that the Transaction 
does not raise serious doubts as to its compatibility with the internal market or the 
functioning of the EEA agreement as a result of a horizontal effects in the market for  
sore throat remedies in the form of aerosols/sprays in France . 
4.1.4.3.   Mouth pain relief liquids in France  
(78) The Parties’ activities  in this product category in France give rise to a Group 1/1+ 
horizontally affected market only at CHC4 level ( 02D1L – Mouth Pain Re lief – 
Liquids (Topical) ).74 
(79) Cooper markets products under the brand names Hyalugel and Dentobaume. 
Hyalugel is a mouthwash based on hyaluronic acid used to treat irritant conditions of 
the gums (e.g. inflammation of the gums, bleeding, receding gums) or tr aumatic 
conditions of the gums (e.g. due to cleaning, abrasion, extraction of teeth). As such, 
Hyalugel is recommended by dentists and practitioners as part of healing treatments. 
Dentobaume is a local anaesthetic indicated for the treatment of acute gingi vodental 
pain. The product is liquid is and applied by a soaked pad directly on the painful 
gum or tooth. In 2020, Dentobaume represented [60-70]%  of Cooper’s sales in this 
market.  
(80) Recordati markets Aphtavea, a mouthwash based on hyaluronic acid and aloe v era to 
treat mouth ulcers and mouth injury. Aphtavea provides a protective mechanical 
barrier over aphthous ulcers or oral lesions, isolating it from potential external 
influences, such as food particles or hot liquids.  
(81) The Notifying Party submits that the  Transaction does not give rise to competition 
concerns in mouth pain relief products in the form of liquids because the Parties’ 
products are not close competitors, the Parties will continually consider their 
competitors and there is vibrant competition w ith recent entrants.75 
                                                 
71  Replies to Questionnaire Q1, question 11.  
72  Form CO, Annex 7.4 -XV-1 – Recordati’s add itional ordinary course documents prepared in 2019 and 
2020, page 2.  
73  Replies to Questionnaire Q1, question 13 and Questionnaire Q2, question 11. No customer raised 
competition concerns regarding the impact of the Transaction in sore throat remedies in the form of 
aerosols/sprays in France. Only one competitor of the Parties considered that the Transaction could have 
a negative impact on the market (leading to higher prices). However, this competitor did not substantiate 
its concerns. Instead, this same competitor identified “ 16 other sore throat sprays brands ” that would 
compete with the combined entity and admitted that the Parties’ products do not compete closely with 
each other (see Replies to Questionnaire Q1, questions 8, 12.1, and 13).  
74  At ATC3/CHC3 level (02D1 – Mouth Pain Relief), the Parties’ market shares result in a Group 3 affected 
market. The Parties’ products do not overlap at molecule level.  
75  Form CO, paragraphs 379 ff.  

 
26  The fact that Aphtavea is not a close competitor to Hyalugel  (which 
represents more than [60-70]%  of Coopers’ sales by value ),78 is reflected in a 
response  of a competitor  to the market investigation, which indicate s that the 
closest substitutes to Hyalugel are Bioxaphte (a product marketed by Bausch 
Health), and Urgo Dentilia and Mercurochrome (marketed by Urgo)  and not 
Aphtavea 79 since  “The two brands selected are we believe as strong as 
Hyalugel. A pharmacist could  easily recommend one or another.” 
Consequently, the bulk of the Cooper’s sales are for a product which is not 
seen as a close competitor o f CVC Recordati . 
The share increment contributed by CVC Recordati is limited to [0-5]% in 
value , so the Transaction w ill not significantly affect the competitive 
landscape in this market. T he Parties would continue facing competitive 
constraints from several competitors with shares higher or equal to that of 
CVC Recordati. These include Bausch Health ( [20-30]%  value shar e in 
2020), Urgo ( [5-10]% ), Groupe Batteur ( [5-10]% ), and Aboca ( [0-5]%). 
The results of the market investigation confirm that post -Transaction a 
sufficient number of suppliers will offer mouth pain relief liquids in France.80 
The same competitor states: “Mouth pain relief products exist in different 
formats. The liquid form is popular but gels are also very common. Plus 
some mouthwashes can also be used to treat mouth pain relief (eg. Eludril). 
Therefore plenty of products exist on the market.”81 
 
(b) There is  some evidence of new entrants into this market, suggesting that 
barriers to entry are not high. Urgo and Aboca entered the market only in 
2020 and already have market shares comparable or higher to that of Cooper.  
 
(c) The market investigation did not reveal  any concerns in relation to mouth 
pain relief products in the form of liquids in France.82  
(85) In light of the above considerations, the Commission concludes that the Transaction 
does not raise serious doubts as to its compatibility with the internal market o r the 
functioning of the EEA agreement as a result of horizontal effects in the market for 
mouth pain relief products in the form of liquids in France.  
4.1.4.4.   Ear care products in Spain  
(86) The Parties’ activities  in this product category in Spain give rise to a Gro up 1/1+ 
horizontally affected market only at CHC4 level ( 08A1Z – Ear Care – Other 
Forms ).83  
                                                 
78  Form CO Table 11  
79  Reply to Questionnaire Q5, question 7. “The two brands selected  [ are we believe as strong as Hyalugel. A 
pharmacist could easily recommend one or another.”  
80  Reply to Quest ionnaire Q5, question 9.  
81  Reply to Questionnaire Q5, question 9.  
82  Replies to Questionnaire Q5, questions 12 -13, as well as r eplies to Questionnaire Q1, questions 15 -16 ; to 
Questionnaire Q2, questions 12 -13; to Questionnaire Q3, questions 17 -18 ; to Qu estionnaire Q4, questions 
13-14.  


 
29 (c) Again, even if the Parties were to compete in this market , Post-Transaction, the 
combined entity would continue facing competitive constraints from several 
competitors with shares higher than that of CVC Recordati. These include Faes 
Farma ( [20-30]%  in value and [10-20]%  in volume in 2020), Perrigo ( [10-20]%  
in value and [10-20]%  in volume) and M4 Pharma ( [10-20]%  in value and [5-
10]%  in volume).  
 
(d) The market investigation did not reveal any concerns in relation to ear care 
products in other forms in Spain.89  
(92) In light of the above considerations, the Commission concludes that the Transaction 
does not raise serious doubts as to its compatibility with the internal market or the 
functioning of the EEA agreement as a result of a horizontal effects in the m arket for 
ear care products in other forms in Spain.  
4.1.4.5.   Antitussives (in combination) in Luxembourg  
(93) Antitussives90 (also known as cough suppressants), relieve coughs by blocking the 
cough reflex, and are most effective at relieving dry coughs. The ATC4 class R5D2 , 
the only class where the Parties’ activities in antitussives give rise to an affected 
market,  includes antitussives in combinations with expectorants, antihistamines, 
ephedrine, herbal tinctures, etc.91 
(94) Coopers' Pholco Mereprine is an OTC medicine use d for antitussive effect. It is a 
syrup intended to suppress dry coughs and irritable coughs. Recordati's Neo -Codion 
is a cough suppressant, i.e. used as a treatment that stops the cough reflex. It is used 
to treat dry coughs for adults and children. It is  sold both in Rx and OTC variants.  
(95) Tables 16 and 17 below show the market shares of the Parties and their main rivals 
in the market for antitussives in Luxembourg in the last three years, in value and in 
volume.  
  
                                                 
89  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
90  ATC3 class R5D.  
91  Combinations with analgesics and antipyretics (R5A) and combinations with anti -infectives (R5B) are 
excluded, see https://www.ephmra.org/media/4973/atc -guidelines -2021 -final.pdf, page 133.  

 
31 (96) In 2020, the combined share of the Parties in the market for antitussives in 
combination in Luxembourg was [90-100]%  in value and [90-100]%  in volume 
(with an increment of [0-5]% both in value and in volume contributed by Cooper).  
(97) The Notifying Party submits that these combined shares do not appear to reflect the 
current competitive dynamic s within the market segment R5D2, because regulatory 
changes stemming from the Belgian legislation92 which are expected to be followed 
by Luxembou rg, ban  the combination syrups as of January 2020. As a result, during 
2020, Pholco -Mereprine has been withdrawn from the market and is no longer 
marketed in the EEA. Its replacement, Pholco Mereprine Mono is not part of the 
ATC4 class R5D2, but of R5D1. Thus, the overlap in the ATC4 class R5D2 is only 
historical and will not persist in the future.93 Additionally, one of the largest market 
participants, Klosterfrau, is no longer included in the IQVIA data set in the R5D2 
class for 2020, while it had market shares of more than approximately [20-30]%  in 
the previous years. 94 Finally, the Notifying Party notes that the overall sales in this 
market decreased by around [70-80]% , further proof that other players also had 
fewer sales.  
(98) Moreover , the Notifying Party underlines that the two do not contain the same 
molecules95 and can also be distinguished based on the different forms in which they 
are marketed and used. Vemedia's Pholco Mereprine is sold in the form of a syrup, 
while Recordati's Neo -Codion is sold eithe r in the form of a tablet or in the form of a 
syrup.96 
(99) The Commission takes note that the regulatory changes discussed above, make that 
the Parties no longer overlap in ATC4 class R5D2. Vermedia has replaced Pholco 
Mereprine by Pholco Mereprine Mono, based on the molecule pholcodine (which is 
not contained in Recordati's Neo -Codion). Therefore,  there is no overlap at the 
molecule level.  
(100)  The Commission also notes that in ATC3 class R5D (including both Neo -Codion’s 
R5D2 and Pholco Mereprine’s Mono R5D1), combi ned market shares would be 
below [20-30]% . 
(101)  Finally, the market investigation did not reveal any  concerns in relation to 
antitussives, in combination in Luxembourg.97  
                                                 
92  Decision of the Federal Agency for Medicines and Health Products  ("FAMHP") of Belgium of January 
2020.  
93  See Form CO paragraph 340 and Annex 7.4 -VII 
94  According to the Notifying Party, Klosterfrau was active on the Luxemburg market with a combined 
product named "Toplexil", but this product was withdrawn on 1 Jan 2020  and has not been replaced by an 
alternative, see Form CO, footnote 156.  
95  Vemedia's Pholco Mereprine has been a combined syrup based (until May 2020 ), on the  following  
ingredients  benzoic acid, doxylamine, pholcodine and sulfogaiacol. On the other hand, Recordati's  Neo-
Codion, is based on ascorbic acid, bromoform, codeine, benzoic acid, bromine,  adiantum capillus veneris, 
drosera rotundifolia, grindelia robusta, papaver rhoeas, polygala senega, senna, sulfogaiacol and thymus 
serpyllum. Therefore the Parti es' products are considered antitussives in combinations (R5D2) rather than 
plain antitussives (R5D1) have only two molecules in common (sulfogaiacol, an expectorant, and benzoic 
acid, a preservative). See Form CO paragraph 339.  
96  See Form CO paragraph 34 1 and footnote 148. 
97  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  



 
35 (111)  The market investigation did not provide any indications that would require the 
Commission to depart from its previous decisional practice with respect to the 
product market definition for FDPs that are vertically affected.  
(112)  The precise delineation of the FDP market(s ) that are vertically affected by the 
Transaction can be left open because no competition concerns arise under any 
plausible relevant market definition.  
(B) Geographic market definition  
(113)  As explained above,104 the Commission consistently defines the different pla usible 
markets for FDPs as national in scope.  
(114)  The market investigation did not provide any indications that would require the 
Commission to depart from its previous decisional practice on the geographic scope 
of the different plausible markets for FDPs tha t are vertically affected.  
(115)  Therefore, for the purposes of this decision, the Commission considers the 
geographic scope of the different plausible markets for FDPs to be national in scope.  
4.2.2.2.  Flexible packaging for pharmaceuticals  
(A) Product market definition  
(116)  Previously the Commission described the production of flexible packaging as the 
manufacture, supply and conversion of plastic and cellulose films, aluminium foils 
and papers into reels of packaging.105 
(117)  The Commission previously considered that flexible packagi ng could be segmented 
by distinguishing the end -use of the packaging. That is, distinct product markets 
exist for flexible packaging for: (i) food, (ii) medical supplies, (iii) pharmaceuticals, 
(iv) household products, and (v) other non -food.106 
(118)  With respect  to flexible packaging for pharmaceuticals, the Commission has 
previously considered a narrower segmentation into (a) laminated sachets, (b) 
coldform blister bases, (c) plastic -based blister bases and (d) blister lidding, but 
ultimately left the product ma rket definition open.107 
(119)  The Notifying Party submits that there is a high degree of supply -side substitutability 
within all types of flexible packaging,108 but does not contest the Commission’s 
decisional practice.  
(120)  The Commission’s investigation did not provid e any indications that it would be 
appropriate for the Commission to depart from its previous decisional practice to 
consider a distinct market for flexible packaging for pharmaceuticals.  
                                                                                                                                                      
103  See Section 4.1.2 . 
104  See Section 4.1.2 . 
105  Case M.909 4 – Amcor/Bemis, paragraph 13.  
106  Case M.9094 – Amcor/Bemis, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 15; Case M.3225 – 
Alcan/Pechiney, paragraphs 128 and 131.  
107  Case M.8107 – CVC/AR Packaging, paragraph 12; Case M.5599 – Amcor/Alcan, paragraph 13. 
108  Form CO, paragraph 94.  
 
36 (121)  In this case, the question of whether the market for flexible packag ing for 
pharmaceuticals should be further segmented in line with the four segments listed at 
paragraph (118)  above, can be left open since the Transa ction does not give rise to 
serious doubts as to its compatibility with the internal market or the functioning of 
the EEA agreement under any of these narrower plausible market definitions.  
(B) Geographic market definition  
(122)  The Commission has previously conside red the geographic scope of markets for 
flexible packaging for pharmaceuticals as EEA -wide or wider.109 
(123)  The Notifying Party agrees with the previous Commission decisions that the 
geographic market for flexible packaging is EEA -wide or wider.110 
(124)  The Commission’ s investigation did not provide any indications that would require 
the Commission to depart from its previous decisional practice that the geographic 
market for flexible packaging for pharmaceuticals is at least EEA -wide.  
(125)  Therefore, for the purposes of th is decision, the Commission considers the 
geographic scope for flexible packaging for pharmaceuticals to be at least EEA -
wide.  
4.2.2.3.  Packaging machinery for the pharmaceutical sector  
(A) Product market definition  
(126)  The Commission has not considered the market for packaging machinery in its 
previous Decisions.  
(127)  The Notifying Party explains that there is typically competitive interaction between 
the different formats, types of machines and/or technologies, as customers  would 
typically purchase a range of packaging machines and technologies that could be 
applied to different categories/sectors, as opposed to a single type of packaging 
machinery or technology for a specific type of product.111 However, t he Notifying 
Party s ubmits that, on the narrowest plausible basis, the market for packaging 
machinery could be defined by reference to end -use (e.g. packaging machinery for 
the pharmaceutical sector, medical sector etc.).112 
(128)  The Commission’s investigation did not provide any in dications as to the appropriate 
level for defining the market for packaging machinery.  The question of whether the 
relevant product market includes all packaging machinery, or packaging machinery  
for the pharmaceutical  sector only, can be left open since t he Transaction does not 
give rise to serious doubts as to its compatibility with the internal market or the 
functioning of the EEA agreement under any plausible product market definition.  
                                                 
109  Case M.8107 – CVC/AR Packaging, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 48.  
110  Form CO, paragraph 121.  
111  Form CO, paragraph 109.  
112  Form CO, paragraph 109.  
 
37 (B) Geographic market definition  
(129)  The Commission has not previously consi dered the geographic scope of markets for 
packaging machinery . 
(130)  The Notifying Party submits  that the geographic market for packaging machinery 
(including for packaging machinery for the pharmaceutical sector) is EEA -wide or 
wider.113 
(131)  The Commission’s investig ation did not provide any indications as to the appropriate 
geographic scope of the market for packaging machinery (or packaging machinery 
for the pharmaceutical sector) .  
(132)  Therefore, for the purposes of this decision, the Commission considers the 
geographi c scope for packaging machinery for pharmaceuticals to be at least EEA -
wide.  
4.2.2.4.  APIs  
(A) Product market definition  
(133)  Active pharmaceutical ingredients (“APIs”) are the molecules (under patent or 
expired) that are used to manufacture FDPs.114 
(134)  Per the Commission’s de cisional practice, in principle, each API belongs to a 
separate product market but substitutability between APIs, either in general , or for 
certain applications must also be considered.115  
(135)  The Notifying Party agrees with the decisional practice of the Commi ssion regarding 
the product market definition in APIs.116 
(136)  The Commission’s investigation did not provide any indications that it would be 
appropriate for the Commission to depart from its previous decisional practice for 
APIs.  
(137)  In this case, the exact product  market definition for APIs can be left open since the 
Transaction does not give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement under any plausible market 
definition.  
(B) Geographic market defini tion 
(138)  The Commission has previously considered the geographic scope for APIs is at least 
EEA -wide.117  
(139)  The Notifying Party did not depart from the decisional practice of the Commission 
regarding the geographic market definition in APIs. 118 
                                                 
113  Form CO, paragraph 122.  
114  Case M.6278 – Takeda/Nycomed, para. 16.  
115  Case M. 7746 – Teva/Allergan Generics , paras. 644, 645.  
116  Form CO, paragraph 81.  
117  Case M. 7746 – Teva/Allergan Generics , paras. 646, 647.  
 
38 (140)  The Commission’s inv estigation did not provide any indications that it would be 
appropriate for the Commission to depart from its previous decisional practice for 
APIs.  
(141)  In this case, the exact geographic market definition for APIs can be left open since 
the Transaction does n ot give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement under any plausible market 
definition.  
4.2.2.5.  Excipients  
(A) Product market definition  
(142)   (Pharmaceutical) excipients are inert substances with whic h the API is combined to 
form an FDP.  
(143)  In Ashland/International Specialty Products , the Commission considered 
pharmaceutical excipients belong to separate relevant markets based on the 
substance from which each excipient was made (e.g., lactose, starch, ce llulose)  and 
considered plausible markets for binders, coatings and plausible narrower 
segments .119 In Friesland Foods/Campina , the Commission defined even narrower 
markets for lactose excipients, namely separate markets for (i) wet granulation 
lactose and ( ii) direct compression lactose.120  
(144)  The Notifying Party did not depart from the decisional practice of the Commission 
regarding product market definition in pharmaceutical excipients.  
(145)  The Commission’s investigation did not provide any indications that would  require 
the Commission to depart from its previous decisional practice to consider separate 
markets for excipients based on their substance ingredients and to sub -segment the 
market for lactose into (i) wet granulation lactose and (ii) direct compression lactose.  
(B) Geographic market definition  
(146)   In Ashland/International Specialty Products  and in Friesland Foods/Campina, the 
Commission found that the scope of the relevant markets for excipients is at least 
EEA -wide.121  
(147)  The Notifying Party did not depart from t he decisional practice of the Commission 
regarding geographic market definition in pharmaceutical excipients.  
(148)  The Commission’s investigation did not provide any indications that would require 
the Commission to depart from its previous decisional practice to consider at least 
EEA -wide markets for excipients based on their substance ingredients and to sub -
segment the market for lactose into (i) wet granulation lactose and (ii) direct 
compression lactose.  
                                                                                                                                                      
118  Form CO, paragraph 113.  
119  Case M.6313 – Ashland/International Spe ciality Products , para. 12.  
120  Case M.5046 – Friesland Foods/Campina , paras. 1622 and 1652, 1656  
121  Case M.6313 – Ashland/International Speciality Products , para. 26.  
 
39 4.2.2.6.  CDMO services to pharmaceutical companies  
(A) Product mark et definition  
(149)  Contract development and manufacturing organisations (“CDMOs”) provide 
manufacturing services for FDPs and APIs to third -party pharmaceutical companies.  
(150)  In the past, the Commission distinguished (i) a CDMO market for FDPs and (ii) a 
CDMO mar ket for APIs.122 As regards the CDMO market for FDPs, further 
segmentation was considered based on (i) the pharmaceutical form manufactured 
(e.g., solids, semi -solids, injectables); (ii) the conditions of manufacture (e.g., 
toxicity, sterile environment); (i ii) the type of API used for its production and the 
delivery mechanism used (e.g., swallowing, intravenous, injection, etc.).123 The 
Commission also examined whether there is a separate market for contract 
manufacturing organization (“CMO”) services but even tually left the question 
open.124  
(151)  The Notifying Party submits that irrespective of the precise market definition and 
even based on the narrowest plausible market segment, the Transaction would not 
lead to competitive concerns.125 
(152)  The Commission’s investigatio n did not provide any indications that it would be 
appropriate for the Commission to depart from its previous decisional practice for 
CDMOs.  
(153)  In this case, the exact product market definition for CDMOs can be left open since 
the Transaction does not give ri se to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement under any plausible market 
definition.  
(B) Geographic market definition  
(154)  The Commission added that the geographic scope of all plausible CDMO services 
markets is at least EEA -wide.126  
(155)  The Notifying Party did not depart from the decisional practice of the Commission 
regarding the geographic market definition for CDMOs. 127 
(156)  The Commission’s investigation did not provide any indications that it would be 
approp riate for the Commission to depart from its previous decisional practice for 
CDMOs.  
(157)  In this case, the exact geographic market definition for CDMOs can be left open 
since the Transaction does not give rise to serious doubts as to its compatibility with 
the internal market or the functioning of the EEA agreement under any plausible 
geographic market definition for CDMOs.  
                                                 
122  Case M.9315 – CHR. Hansen/Lonza/JV, para. 17 .  
123  Case M.9315 – CHR. Hansen/Lonza/JV, para. 22 . 
124  Case M.9315 – CHR. Hansen/Lonza/JV, para. 19.  
125  Form C0, paragraph 105.  
126  Case M.9315 – CHR. Hansen/Lonza/JV, para. 24 . 
127  Form C0, paragraph 116.  
 
40 4.2.2.7.  Private hospital services  
(A) Product market definition  
(158)  In CVC/Recordati , the Commission considered a relevant product market for private 
hospi tal services which would be separate from public hospital services, depending 
on the specificities of the case and the national market in question.128 
(159)  The Notifying Party acknowledges the past decisional practice of the Commission 
and submits that the issue can be left open, since the Transaction would not lead to 
competitive concerns even if a product market for private hospital services were to 
be considered.129 
(160)  The Commission’s investigation did not provide any indications that it would be 
appropriate for th e Commission to depart from its previous decisional practice for 
private hospital services.  
(161)  In this case, the product market definition for hospital services can be left open since 
the Transaction does not give rise to serious doubts as to its compatibility with the 
internal market or the functioning of the EEA agreement even under the narrowest 
plausible product market definition of private hospital services.  
(B) Geographic market definition  
(162)  The Commission found that the geographic scope of this ma rket is national or 
narrower.130  
(163)  The Notifying Party did not depart from the decisional practice of the Commission 
regarding market definition in private hospital services.  
(164)  The Commission’s investigation did not provide any indications that it would be 
appropriate for the Commission to depart from its previous decisional practice for 
private hospital services.  
(165)  In this case, the exact geographic market definition for private hospital services can 
be left open since the Transaction does not give rise to seriou s doubts as to its 
compatibility with the internal market or the functioning of the EEA agreement 
under any plausible product market definition of private hospital services.  
4.2.3.  Legal framework  
(166)  A concentration can also entail vertical and/or conglomerate effec ts. The 
Commission Guidelines on the assessment of non -horizontal mergers under the 
Merger Regulation131 (the “Non -Horizontal Merger Guidelines”) distinguish 
between two main ways in which non -horizontal mergers may significantly impede 
effective competition : (a) when they give rise to input and/or customer foreclosure 
(non-coordinated effects); and (b) when the merger changes the nature of 
                                                 
128  Case M.9044 – CVC/Recordati , paras. 21 and 145.  
129  See Form CO, paragraph 184 (c) (i)  
130  Case M.9044 – CVC/Recordati , para. 22.  
131 Commission Guidelines on the assessment of non -horizontal mergers under the Merger Regulation ( OJ 
C 265, 18.10.2008, p. 6).  
 
41 competition in such a way that firms that previously were not coordinating their 
behaviour, are now more likely to coord inate to raise prices or otherwise harm 
effective competition (coordinated effects).132 The Non -Horizontal Merger 
Guidelines distinguish two types of foreclosure: (a) where the merger is likely to 
raise the costs of downstream rivals by restricting their acc ess to an important input 
(input foreclosure) and (b) where the merger is likely to foreclose upstream rivals by 
restricting their access to a sufficient customer base (customer foreclosure)133.  
(167)  In assessing the likelihood of an anticompetitive input forecl osure strategy, the 
Commission has to examine whether (i) the merged entity would have the ability to 
substantially foreclose access to inputs; (ii) whether it would have the incentive to do 
so; and (iii) whether a foreclosure strategy would have a signifi cant detrimental 
effect on competition downstream.134 In assessing the likelihood of an 
anticompetitive customer foreclosure strategy, the Commission has to examine 
whether (i) the merged entity would have the ability to foreclose access to 
downstream market s by reducing its purchases from upstream rivals; (ii) whether it 
would have the incentive to do so; and (iii) whether a foreclosure strategy would 
have a significant detrimental effect on consumers in the downstream market.135 
According to the Non -Horizonta l Merger Guidelines, the Commission is unlikely to 
find concern in non -horizontal mergers, where the market share post -merger of the 
new entity in each of the markets concerned is below 30%.136  
(168)  The Non -Horizontal Merger Guidelines define conglomerate merger s as mergers 
between firms that are in a relationship which is neither horizontal (as competitors in 
the same relevant market) nor vertical (as suppliers or customers).137 
4.2.4.  Competitive assessment  
4.2.4.1.  Flexible Packaging for Pharmaceuticals – CVC (Upstream) / FDPs  – Target 
(Downstream)  
(169)  One of the CVC portfolio companies, Syntegon, is active in the upstream market for 
flexible packaging for pharmaceuticals in the EEA. Flexible packaging is an input 
for several FDPs of the Target (downstream). The vertically linked upstream and 
downstream markets and the Parties’ shares are identified in Appendix 1. As shown 
in this Appendix, CVC Syntegon’s share in all upstream markets (that is in flexible 
packaging for the pharmaceutical sector and narrower plausible segments for 
laminated sachets, coldform blister bases, plastic -based blister bases and blister 
lidding) is 10% or less while Cooper’s share is 30% or more in all the downstream 
markets.  
(170)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets for flexible 
packaging for pharmaceuticals (under any plausible market delineation) in the EEA, 
where it is active. CVC Syntegon holds a share of 10% or less in the upstream 
                                                 
132  Non-horizontal Merger Guidelines, paragraphs 17 -19. 
133  Non-horizontal Merger Guideline s, paragraph 30.  
134  Non-horizontal Merger Guidelines, paragraph 32.  
135  Non-horizontal Merger Guidelines, paragraph 59.  
136  Non-horizontal Merger Guidelines, paragraph 25.  
137  Non-horizontal Merger Guidelines, paragraph 5.  
 
42 markets for  flexible packaging for pharmaceuticals (under any plausible market 
delineation) in the EEA and it would face competition from several players, 
including Amcor, Wipak, Constantia Flexibles and others. Post -Transaction, the 
Target’s downstream rivals could turn to any of CVC’s rivals (at least CVC’s rivals 
in the EEA or possibly to an even wider set of rivals if the geographic upstream 
market is defined as wider than the EEA) to source flexible packaging, even if the 
combined entity decided to discontinue su pply of its upstream inputs.  
(171)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for flexible packaging of 
pharmaceuticals (or any plausible market delineation) in the EEA. Rather, Cooper’s 
demand for any flexible packaging of pharmaceuticals in the upstream markets does 
not exceed 10% of the total EEA -wide demand.138 That is because flexible 
packaging used for individual FDPs of Cooper is used for a variety o f other use 
cases, including for example other FDPs where Cooper’s market share is limited. In 
case the combined entity decided to source flexible packaging that CVC Syntegon 
offers today only in -house, CVC’s rivals (both its rivals in the EEA or in a wider 
market) would continue to have access to a significant customer base to sell their 
products.  
(172)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in FDPs or its upstream rivals in the provision of flexible 
packaging for pharma ceuticals in the EEA  (or wider) , it would also not have an 
incentive to attempt a foreclosure as it would not be able to gain anything from such 
a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the 
combined entity would h ave no impact on the national markets for FDP and the 
market for flexible packaging for pharmaceuticals in the EEA  (or wider) . In any 
event, no respondent to the market investigation raised concerns regarding the 
impact of the proposed Transaction on these  vertically linked markets. 139 
4.2.4.2.  Packaging Machine ry for Pharmaceuticals – CVC (Upstream) / FDPs – Target 
(Downstream)  
(173)  One of the CVC portfolio companies, AR Packaging, is active in the plausible 
upstream market for packaging machines (for pharmaceuticals ) in the EEA. Such 
machines are used to manufacture several FDPs of the Target (downstream). The 
vertically linked upstream and downstream markets and the Parties’ shares are 
identified in Appendix 2. As shown in this Appendix, CVC AR Packaging’s share in 
all plausible upstream markets (that is in packaging machine ry or packaging 
machine ry for pharmaceuticals) is 10% or less while the Target’s share is 30% or 
more in all the downstream markets.  
                                                 
138  Cooper’s share of 30% or more are based on markets defined at ATC3/CHC3, ATC4/CHC4, or molecule 
level (or in case of anti -lice products on GERS data). Cooper’s high market shares in a few countries 
concerning a small number of FDPs (and often under narrow market delineations) do not give the 
combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 – 
Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi -
Aventis/Zentiva, para. 533.)  
139  Replie s to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
 
43 (174)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets (for 
packaging machine ry or packaging machinery  for pharmaceuticals ) in the EEA, 
where it is active. CVC AR Packaging holds a share of 10% or less in the upstream 
market s for packaging machinery  (under any plausible market delineation) in the 
EEA and it would face competition from several players, including IMA Group, 
Bausch & Ströbel, Optima and others. Post -Transaction, the Target’s downstream 
rivals could turn to any o f CVC’s rivals (at least CVC’s rivals in the EEA or possibly 
to an even wider set of rivals if the geographic upstream market is defined as wider 
than the EEA) to source packaging machines, even if the combined entity decided to 
discontinue supply of its u pstream inputs.  
(175)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for packaging machines for 
pharmaceuticals (or any narrower plausible market) in the EEA. Rather, the Target’s 
demand for any packaging machines for pharmaceuticals in the upstream markets 
does not exc eed 10% of the total EEA -wide demand.140 That is because the 
packaging machinery used for FDPs by Cooper is also used for a variety of other 
packaging purposes , and because , according to the Parties,  Cooper only procures 
packaging machinery in case of an exp ansion or to replace obsolete packaging 
machinery.141 In case the combined entity decided to source packaging machine that 
CVC AR Packaging offers today only in -house, CVC’s rivals (both its rivals in the 
EEA or in a wider market) would continue to have acce ss to a significant customer 
base to sell their products.  
(176)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in national markets for FDPs or its upstream rivals in the 
provision of packaging machines for pharmaceu ticals in the EEA  (or wider) , it 
would also not have an incentive to attempt a foreclosure as it would not be able to 
gain anything from such a strategy. In the absence of the ability to foreclose, any 
foreclosure strategy by the combined entity would have  no impact on the national 
markets for FDP and the market for packaging machines for pharmaceuticals in the 
EEA  (or wider) . In any event, no respondent to the market investigation raised 
concerns regarding the impact of the proposed Transaction on these ve rtically linked 
markets. 142 
4.2.4.3.  APIs – CVC’s Recordati (Upstream) / FDPs – Cooper (Downstream)  
(177)  CVC is active in the upstream API markets for (i) diphenhydramine hydrochloride in 
the EEA and (ii) dimenhydrinate in the EEA. These APIs are inputs to 15 FDPs 
marke ted by Cooper downstream. The vertically linked upstream and downstream 
markets and the Parties’ shares are identified in Appendix 4.  
                                                 
140  Cooper’s share of 30% or more are based on markets de fined at ATC3/CHC3, ATC4/CHC4, or molecule 
level (or in case of anti -lice products on GERS data). Cooper’s high market shares in a few countries 
concerning a small number of FDPs (and often under narrow market delineations) do not give the 
combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 – 
Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi -
Aventis/Zentiva, para. 533.)  
141  Form CO, paragraph 251.  
142  Replies to Questionnaire Q1, que stions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
 
44 (178)  In 2020, the Target sourced diphenhydramine hydrochloride from CVC worth 
approximately EUR […] (or [5-10]%  of CVC’s total sales in the EEA for this API). 
143 The Target has not sourced dimenhydrinate since 2018 due to sufficient material 
in stock. 144 
(179)  The combined entity is unlikely to have the ability to engage in input foreclosure  for 
either of these products. F irstly, for diphenhydramine hydrochloride, since it is a 
product which can be manufactured easily and which is sold by a number of 
companies globally and in Europe, e.g. by Caesar & Loretz GmbH, Tiefenbacher 
API + Ingredients, LGC Limited, Wanbury Limited and Kongo Chemical Co. 
Limited. All these suppliers would be able to supply Cooper’s downstream rivals. 
Given Cooper’s low market shares in the downstream markets (overall sales values 
of less than EUR 1m), Recordati would have to forego all or the vast ma jority of its 
sales for diphenhydramine hydrochloride in the EEA. Regarding dimenhydrinate the 
fact that for the last three years the Target has not sourced it demonstrates the low 
importance of the product and therefore the lack of any ability to foreclos e. 
(180)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for diphenhydramine 
hydrochloride or dimenhydrinate in the EEA  or wider . In 2020 Cooper’s purchases 
of diphenhydr amine hydrochloride amounted to approximately EUR […] ([5-10]%  
of the total of Recordati's total EEA sales for that year ).145 
(181)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in the national markets for FDPs or its  upstream rivals in APIs in 
the EEA  or wider , it would also not have an incentive to attempt a foreclosure as it 
would not be able to gain anything from such a strategy. In the absence of the ability 
to foreclose, any foreclosure strategy by the combined entity would have no impact 
on the national markets for FDPs and the market for APIs in the EEA  or wider . In 
any event, no respondent to the market investigation raised concerns regarding the 
impact of the proposed Transaction on these vertically linked ma rkets. 146 
4.2.4.4.  APIs – Target (Upstream) / FDPs – CVC (Downstream)  
(182)  The Target is active in different upstream markets for APIs in the EEA. These APIs 
can be an input for a number of FDPs of CVC’s Recordati and Genetic 
(downstream). The vertically linked ((at the  ATC3/CHC3, ATC4/CHC4 and 
molecule levels)) upstream and downstream markets and the Parties’ shares are 
identified in Appendix 6  (under all plausible market definitions) . As shown in this 
Appendix, Cooper’s share in all upstream markets is 10% or less whil e CVC’s 
Recordati and Genetic’s share is 30% or more in all the downstream markets.  
(183)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets for APIs in 
the EE A, where it is active. Under all plausible market definitions, the Target holds a 
                                                 
143 Form CO, footnote 88.  
144 Form CO, footnote 106  
145  See Form CO, footnote 88.  
146  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
 
45 share of 10% or less in the upstream markets for APIs in the EEA147 and it would 
face competition from several players, Brenntag, Univar, Helm, IMCD and others.148 
Post-Transacti on, Recordati’s and Genetic’s downstream rivals could turn to any of 
Cooper’s rivals (at least Cooper’s rivals in the EEA or possibly to an even wider set 
of rivals if the geographic upstream market is defined as wider than the EEA) to 
source APIs, even if  the combined entity decided to discontinue supply of its 
upstream inputs.  
(184)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for APIs in the EEA  or wider 
market . Rath er, Recordati’s and Genetic’s demand for any APIs in the upstream 
markets does not exceed 10% of the total EEA -wide demand. In case the combined 
entity decided post -Transaction to source the APIs that Cooper offers today only in -
house, Cooper’s rivals woul d continue to have access to a significant customer base 
to sell their products.  
(185)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in the national markets for FDPs or its upstream rivals in APIs, it 
would also no t have an incentive to attempt a foreclosure as it would not be able to 
gain anything from such a strategy. In the absence of the ability to foreclose, any 
foreclosure strategy by the combined entity would have no impact on the national 
markets for FDPs an d the market for APIs. In any event, no respondent to the market 
investigation raised concerns regarding the impact of the proposed Transaction on 
these vertically linked markets. 149 
4.2.4.5.  Excipients – Cooper (Upstream) / FDPs – CVC’s Recordati and Genetic 
(Downs tream)  
(186)  The Target is active in different upstream markets for pharmaceutical excipients in 
the EEA. These excipients can be an input for several FDPs of CVC’s Recordati and 
Genetic (downstream). The vertically linked upstream and downstream markets and 
the Parties’ shares are identified in Appendix 5. As shown in this Appendix, 
Cooper’s share in all upstream markets  (even under the narrowest plausible markets 
defined at the level of individual excipients)  is 10% or less while CVC’s Recordati 
and Genetic’s share is 30% or more in all the downstream markets.  
(187)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets for 
excipients in the EEA, where it is active. Und er all plausible market definitions, 
Cooper holds a share of 10% or less in the upstream markets for excipients in the 
EEA150 and it would face competition from several players, including Brenntag, 
Safic Alcan, Quimdis, and others. Post -Transaction, Recordati’s and Genetic’s 
downstream rivals could turn to any of Cooper’s rivals (at least Cooper’s rivals in 
the EEA or possibly t o an even wider set of rivals if the geographic upstream market 
is defined as wider than the EEA) to source excipients, even if the combined entity 
decided to discontinue supply of its upstream inputs.  
                                                 
147  See Form CO, Annex 6.4 – Overview of vertical rel ationships (affected markets).  
148  See Form CO, footnote 117.  
149  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, que stions 12 -13.  
150  See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).  
 
46 (188)  The combined entity is unlikely to have the ability to  engage in customer foreclosure  
because it would not constitute an important customer for excipients in the EEA. 
Rather, Recordati’s and Genetic’s demand for any excipients in the upstream 
markets does not exceed 10% of the total EEA -wide demand.151 In case the 
combined entity decided to source the excipients that Cooper offers today only in -
house, Cooper’s rivals (both its rivals in the EEA or in a wider market) would 
continue to have access to a significant customer base to sell their products.  
(189)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in the national markets for FDP and or its upstream rivals in 
excipients in the EEA  (or wider) , it would also not have an incentive to attempt a 
foreclosure as it would not b e able to gain anything from such a strategy. In the 
absence of the ability to foreclose, any foreclosure strategy by the combined entity 
would have no impact on the national markets for FDPs and the market for 
excipients in the EEA  (or wider) . In any even t, no respondent to the market 
investigation raised concerns regarding the impact of the proposed Transaction on 
these vertically linked markets.152  
4.2.4.6.  Excipients (Wet granulation lactose and direct compression lactose) – CVC’s DFE 
Pharma (Upstream) / FDPs and  CDMO services – Cooper (Downstream)  
(190)  DFE Pharma (a portfolio company controlled by CVC) is active in the upstream 
markets for wet granulation lactose and direct compression lactose in the EEA. 
These excipients are used as inputs for FDPs of Cooper in 12 d ownstream markets 
and for CDMO services that Cooper offers to third parties. The vertically linked 
upstream and downstream markets and the Parties’ shares are identified in Appendix 
3. As shown in this Appendix, DFE Pharma’s share in the upstream markets i s 
slightly above 30% while Cooper’s share is less than 30% in all the downstream 
markets.  
(191)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in the upstream markets. In 2020, DFE 
Pharm a held shares of [30-40]%  in wet granulation lactose and [30-40]%  in direct 
compression lactose in the EEA but it faced competition from major international 
rivals  in the EEA153, e.g., Meggle  ([10-20]%  in wet granulation lactose and [30-
40]%  in direct compre ssion lactose) and  Kerry  ([10-20]%  in wet granulation lactose 
and [5-10]%  in direct compression lactose) . Post -Transaction, Cooper’s downstream 
rivals could turn to any of DFE Pharma’s competitors (at least rivals in the EEA or 
possibly to an even wider se t of rivals if the geographic upstream market is defined 
as wider than the EEA)  to source wet granulation lactose and direct compression 
lactose, even if the combined entity decided to discontinue supply of its upstream 
inputs. e.g., Meggle, Kerry, and Arm or 
(192)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for the upstream inputs in the 
EEA. In 2020, Cooper purchased wet granulation lactose worth EUR […] (which 
repres ents [0-5]% of the total demand for this product) and direct compression 
                                                 
151  See footnote 74 above.  
152  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13. 
153  See Form CO Tables 6 & 8.  
 
47 lactose worth EUR […] (which represents [0-5]% of the total demand for this 
product). In case the combined entity decided to source wet granulation lactose and 
direct compression lact ose only in -house, DFE Pharma’s rivals (both its rivals in the 
EEA or in a wider market) would continue to have access to a significant customer 
base to sell their products.  
(193)  Given that the combined entity would not have the ability to foreclose its 
downst ream rivals in the national markets for FDPs and the market for CDMO 
services in the EEA (or wider), or its upstream rivals in the provision of in wet 
granulation and direct granulation lactose in the EEA (or wider), it would also not 
have an incentive to attempt a foreclosure as it would not be able to gain anything 
from such a strategy. In the absence of the ability to foreclose, any foreclosure 
strategy by the combined entity would have no impact on the national markets for 
FDPs, the market for CDMO serv ices in the EEA (or wider) and the market for in 
wet granulation and direct granulation lactose in the EEA (or wider). In any event, 
no respondent to the market investigation raised concerns regarding the impact of the 
proposed Transaction on these vertica lly linked markets. 154 
4.2.4.7.  CDMO Services – Target (Upstream) / FDPs – CVC (Downstream)  
(194)  The Target is active in the upstream markets for CDMO services in the EEA. These 
CDMO services can be an input for several FDPs of CVC (downstream). For some 
of these FDPs, CVC has a share >30% at national level.  
(195)  The Target is active in different upstream  markets for the provision of CDMO 
services in the EEA. These CDMO servicescan be an input for a number of FDPs of 
CVC’s Recordati and Theramex (downstream). The vertically linked ((at the 
ATC3/CHC3, ATC4/CHC4 and molecule levels)) upstream and downstream 
markets and the Parties’ shares are identified in Appendixes 7i and 7ii  (under all 
plausible market definitions) . As shown in this Appendix, Cooper’s share in all 
upstream markets is 10% or less while CVC’s Recordati and Theramex’s share is 
30% or more in all the downstream markets.  
(196)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets for CDMO 
services in the EEA, where it is active. Under all plausible mark et definitions, The 
Target holds a share of 10% or less in the upstream markets for CDMO services in 
the EEA155 and it would face competition from several players, including Lonza, 
Catalent, Pantheon, Recipharm and others. Post -Transaction, Recordati’s and 
Theramex’s downstream rivals could turn to any of Cooper’s rivals  (at least 
Cooper’s rivals in the EEA or possibly to an even wider set of rivals if the 
geographic upstream market is defined as wider than the EEA)  to source CDMO 
services, even if the combin ed entity decided to discontinue supply of its upstream 
inputs.  
(197)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for CDMO services in the 
EEA. Rather, Recordati’s and Genetic’s demand for any CDMO services in the 
                                                 
154  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
155  See Form CO, Annex 6.4 – Overview of vertical r elationships (affected markets).  
 
48 upstream markets does not exceed 10% of the total EEA -wide demand. In case the 
combined entity decide d post -Transaction to source the CDMO services that Cooper 
offers today only in -house, Cooper’s rivals (both in the EEA or wider) would 
continue to have access to a significant customer base to sell their products.  
(198)  Given that the combined entity would not  have the ability to foreclose its 
downstream rivals the national markets for FDPs, or its upstream rivals in CDMO 
services in the EEA  (or wider) , it would also not have an incentive to attempt a 
foreclosure as it would not be able to gain anything from su ch a strategy. In the 
absence of the ability to foreclose, any foreclosure strategy by the combined entity 
would have no impact on the national markets for FDPs and the market for CDMO 
services in the EEA  (or wider) . In any event, no respondent to the mark et 
investigation raised concerns regarding the impact of the proposed Transaction on 
these vertically linked markets. 156 
4.2.4.8.  FDPs – Target (Upstream) / Private Hospital Services – CVC (Downstream)  
(199)  CVC is active in the downstream market for private hospital ser vices in Greece.157 
Cooper offers FDPs in Greece158 that could be an upstream input for the operation of 
private hospitals downstream. The vertically linked (at the ATC3/CHC3  level ) 
upstream and downstream markets and the Parties’ shares are identified in Appe ndix 
8. 
(200)  The combined entity is unlikely to have the ability to engage in input foreclosure  
because it would not have market power in any of the upstream markets for FDPs in 
Greece. Cooper holds a share of 30% or less in all of the upstream markets for FDPs  
in Greece. Moreover, already now, Cooper does not supply any hospitals in Greece, 
which therefore do not rely on Cooper for the supply of FDPs. Post-Transaction, 
CVC’s downstream rivals could simply keep purchasing the FDPs  from their current 
suppliers , even if the combined entity decided to not supply FDPs  to its downstream 
rivals . 
(201)  The combined entity is unlikely to have the ability to engage in customer foreclosure  
because it would not constitute an important customer for the upstream FDP markets 
in G reece. In a plausible downstream market including all private hospitals in 
Greece, CVC’s hospitals held a share of [30-40]%  in 2020. However, FDPs are used 
by a far wider set of customers other than hospitals, including for example 
wholesalers, drugstores and pharmacies.  In case the combined entity decided to 
source FDPs that Cooper offers today only in -house, CVC’s rivals would continue to 
have access to a significant customer base to sell their products, including both 
private hospitals as well as other t ypes of customers.  
                                                 
156  Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, questions 12 -13; to Questionnaire 
Q3, questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13.  
157 Through the  Hellenic Healthcare Group ("HHG"), which is the largest private hospital group in Greece, 
consisting of six hospitals: Metropolitan Hospital; Metropolitan General; Hygeia Hospital; Mitera; Leto; 
and Creta Interclinic. HHG provides all major procedures and  treats approximately 100,000 inpatients and 
1 million outpatients annually.  
158 These are FDPs in ATC3 class N5B – Hypnotics and Sedatives and in CHC3 class 13A2 – Calming 
Products.  
 
49 (202)  Given that the combined entity would not have the ability to foreclose its 
downstream rivals in the provision of hospital services in Greece its upstream rivals 
in FDPs in Greece, it would also not have an incentive to attempt a foreclos ure as it 
would not be able to gain anything from such a strategy. In the absence of the ability 
to foreclose, any foreclosure strategy by the combined entity would have no impact 
on the market for hospital services in Greece and the market for FDPs in Gre ece. In 
any event, no respondent to the market investigation raised concerns regarding the 
impact of the proposed Transaction on these vertically linked markets. 159 
4.2.4.9.  Overall conclusion on vertical  effects  
(203)  In light of the considerations discussed in paragraph s (169)  to (202) , the 
Commission concludes that the Transaction does not ra ise serious doubts as to its 
compatibility with the internal market or the functioning of the EEA agreement in 
terms of its competition impact on the vertical relationships identified in paragraph 
(109). 
5. CONCLUSION  
(204)  For the above reasons, the European Commission has decided not to oppose the 
notified operation and to declare it compatible with the internal market and with the 
EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the 
Merger Regulation and Article 57 of the EEA Agreement .  
For the Commission  
 
 
(Signed)  
Margrethe VESTAGER  
Executive Vice-President  
 
                                                 
159 Replies to Questionnaire Q1, questions 15 -16 ; to Questionnaire Q2, quest ions 12 -13; to Questionnaire Q3, 
questions 17 -18 ; to Questionnaire Q4, questions 13 -14 ; and to Questionnaire Q5, questions 12 -13. 


































































Appendix 6 
Product Market (Target) Geographic Market Share (2020, EEA) Geographic Market Product Market (ATC3/CHC3) Recordati share in 2020
03D3 ANT DIARR ELECTROL [70-80]%
A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
A7G ORAL ELECTROL. REPLACER[80-90]% by value / [90-100]% 
by volume
BELGIUM 03C4 SALINE LAXATIVES[70-80]% b y value / [30-40]% b y 
volume
SPA N A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
03D3 ANT DIARR ELECTROL [70-80]%A7G ORAL ELECTROL. REPLACER[80-90]% by value / [90-100]% 
by volume
FRANCE N7F DRUGS USED IN OPIOID DEP[30-40]% b
y value / [40-50]% b y 
volume
SPA N A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
06V1 OTHER SKIN PRODUCTS[30-40]% b y value / [50-60]% b y 
volume
D5A TOP ANTIPSORIASIS PRDS[10-20]% b y value / [80-90]% b y 
volume
CYPRUS C5A TOPICAL ANTI-HAEMORRHO DALS[70-80]% b y value / [80-90]% b y 
volume
10A1 ANTIHAEMORRHO DS [30-40]%C5A TOPICAL ANTIHAEMORRHO DL[30-40]% b
y value / [20-30]% b y 
volume
10A1 ANTIHAEMORRHO DS[30-40]% b y value / [30-40]% b y 
volume
C5A TOPICAL ANTIHAEMORRHO DL[30-40]% b y value / [30-40]% b y 
volume
10A1 ANTIHAEMORRHO DS[20-30]% b y value / [30-40]% b y 
volume
C5A TOPICAL ANTIHAEMORRHO DL[50-60]% b y value / [40-50]% b y 
volume
SLOVAKIA C5A TOPICAL ANTIHAEMORRHO DL[20-30]% b y value / [30-40]% b y 
volume
03D3 ANT DIARR ELECTROL [70-80]%A6B BOWEL CLEANSERS[50-60]% b
y value / [40-50]% b y 
volume
A7G ORAL ELECTROL. REPLACER[80-90]% by value / [90-100]% 
by volume
SODIUM BICARBONATE VR.K SPA N A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
03C4 SALINE LAXATIVES [90-100]%
03D3 ANT DIARR ELECTROL [70-80]%
A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
A7G ORAL ELECTROL. REPLACER[80-90]% by value / 90% by 
volume
SODIUM PHOSPHATE MONO PUR CRIST VK SPA N A6B BOWEL CLEANSERS[50-60]% b y value / [40-50]% b y 
volume
CYPRUS C5A TOPICAL ANTI-HAEMORRHO DALS[70-80]% b y value / [80-90]% b y 
volume
10A1 ANTIHAEMORRHO DS [30-40]%C5A TOPICAL ANTIHAEMORRHO DL[30-40]% b
y value / [20-30]% b y 
volume
10A1 ANTIHAEMORRHO DS[30-40]% b y value / [30-40]% b y 
volume
C5A TOPICAL ANTIHAEMORRHO DL[30-40]% b y value / [30-40]% b y 
volumeSORBITOL VR.KDownstream FDP Market (Recordati)
ACIDE CITRIQUE ANH PDRE VR.K
ACIDE PHOSPHORIQUE 85%    VR.L
GLUCOSE ANH VR.K
GLYCERINE CONTAINER 1000 LSPA N
SPA N
At least EEA-wide <10%Case M.10247 - CVC/Cooper
CZECH REPUBLIC
LATVIA
POLAND
ROMANIA
SPA N(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) 
Upstream Market (Target)
SPA N
LATVIA
POLANDICHTHYOLAMMONIUM VR.K
LIDOCAINE CHLTE VR.K
POTASSIUM CHLORURE VR.K
SODIUM CHLORURE VR.K
10A1 ANTIHAEMORRHO DS[20-30]% b y value / [30-40]% b y 
volume
C5A TOPICAL ANTIHAEMORRHO DL[50-60]% b y value / [40-50]% b y 
volume
SLOVAKIA C5A TOPICAL ANTIHAEMORRHO DL[20-30]% b y value / [30-40]% b y 
volumeROMANIA
Appendix 6 
Product Market (Target) Geographic Marke Share (2020, EEA) Geographic Marke Product Market (ATC4/CHC4) Recordati share in 2020
ACIDE CITRIQUE ANH PDRE VR.K FRANCE A6B1 OSMOTIC BOWEL CLEANSERS[40-50]% by value / [5-10]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K GERMANY 03C5P POWDERS[50-60]% by value / [10-20]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K GERMANY A6B1 OSMOTIC BOWEL CLEANSERS[30-40]% by value / [30-40]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K IRELAND 03C4Q ENEMAS[90-100]% by value / [90-100]% 
by volum e
ACIDE CITRIQUE ANH PDRE VR.K ITALY A6B1 OSMOTIC BOWEL CLEANSERS[70-80]% by value / [70-80]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K POLAND A6B1 OSMOTIC BOWEL CLEANSERS[70-80]% by value / [10-20]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K PORTUGAL A6B1 OSMOTIC BOWEL CLEANSERS[80-90]% by value / [80-90]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K SPAIN 03C1Z OTHER FORMS[60-70]% by value / [40-50]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K SPAIN 03D3P POWDER[80-90]% by value / [80-90]% by 
volum e
ACIDE CITRIQUE ANH PDRE VR.K SPAIN A6B1 OSMOTIC BOWEL CLEANSERS[90-100]% by value / [90-100]% 
by volum e
ACIDE CITRIQUE ANH PDRE VR.K SWEDEN A6B1 OSMOTIC BOWEL CLEANSERS[40-50]% by value / [20-30]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L BELGIUM 03C4M MIXTURES (ORAL)[40-50]% by value / [10-20]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L BELGIUM 03C4Q ENEMAS[90-100]% by value / [90-100]% 
by volum e
ACIDE PHOSPHORIQUE 85%    VR.L FRANCE A6B1 OSMOTIC BOWEL CLEANSERS[40-50]% by value / [5-10]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L GERMANY A6B1 OSMOTIC BOWEL CLEANSERS[30-40]% by value / [30-40]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L PORTUGAL 03C4Q ENEMAS[90-100]% by value / [90-100]% 
by volum e
ACIDE PHOSPHORIQUE 85%    VR.L PORTUGAL A6A4 LAXATIVE ENEMAS[70-80]% by value / [60-70]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L PORTUGAL A6B1 OSMOTIC BOWEL CLEANSERS[80-90]% by value / [80-90]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L SPAIN A6A4 LAXATIVE ENEMAS[30-40]% by value / [10-20]% by 
volum e
ACIDE PHOSPHORIQUE 85%    VR.L SPAIN A6B1 OSMOTIC BOWEL CLEANSERS[90-100]% by value / [90-100]% 
by volum e
GLUCOSE ANH VR.K SPAIN 03D3P POWDER[80-90]% by value / [80-90]% by 
volum e
GLYCERINE CONTAINER 1000 L CZECH REPUBLIC 06C4L LIQUIDS&LOTIONS (TOPICAL)[20-30]% by value / [30-40]% by 
volum e
GLYCERINE CONTAINER 1000 L CZECH REPUBLIC 06F3O OINTMENTS/CREAMS[20-30]% by value / [30-40]% by 
volum e
GLYCERINE CONTAINER 1000 L FRANCE A6B1 OSMOTIC BOWEL CLEANSERS[40-50]% by value / [5-10]% by 
volum eCase M.10247 - CVC/Coope r
Downstream FDP Market (Recordati) Upstream Market (Target)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) 
GLYCERINE CONTAINER 1000 L GERMANY A6B1 OSMOTIC BOWEL CLEANSERS[30-40]% by value / [30-40]% by 
volum e
GLYCERINE CONTAINER 1000 L PORTUGAL A6B1 OSMOTIC BOWEL CLEANSERS[80-90]% by value / [80-90]% by 
volum e
GLYCERINE CONTAINER 1000 L SLOVAKIA 06F3O OINTMENTS/CREAMS[20-30]% by value / [40-50]% by 
volum e
GLYCERINE CONTAINER 1000 L SPAIN A6A4 LAXATIVE ENEMAS[30-40]% by value / [10-20]% by 
volum e
GLYCERINE CONTAINER 1000 L SPAIN A6B1 OSMOTIC BOWEL CLEANSERS[90-100]% by value / [90-100]% 
by volum e
ICHTHYOLAMMONIUM VR.K CZECH REPUBLIC 06V1O OINTMENTS/CREAMS[40-50]% by value / [50-60]% by 
volum e
LIDOCAINE CHLTE VR.K LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volum e
LIDOCAINE CHLTE VR.K LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volum e
LIDOCAINE CHLTE VR.K POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volum e
LIDOCAINE CHLTE VR.K SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volum e
LIDOCAINE CHLTE VR.K SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
MANNITOL VR.K SLOVAKIA G4C2 BPH ALPH-ADREN ANTAG PLN[30-40]% by value / [10-20]% by 
volum e
POTASSIUM CHLORURE VR.K SPAIN 03D3P POWDER[80-90]% by value / [80-90]% by 
volum e
SODIUM CHLORURE VR.K SPAIN 03C4Q ENEMAS[90-100]% by value / [90-100]% 
by volum e
SODIUM CHLORURE VR.K SPAIN 03D3P POWDER[80-90]% by value / [80-90]% by 
volum e
SORBITOL VR.K LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volum e
SORBITOL VR.K LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volum e
SORBITOL VR.K LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
SORBITOL VR.K LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
SORBITOL VR.K POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volum e
SORBITOL VR.K POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volum eAt least EEA-wide <10%
SORBITOL VR.K POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volum e
SORBITOL VR.K ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volum e
SORBITOL VR.K ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volum e
SORBITOL VR.K SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volum e
SORBITOL VR.K SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volum e
Appendix 6
Product Market (Target) Geographic Market Share (2020, EEA) Geographic Market Product Market (Molecule ) Recordati share in 202 0
AC DE ASCORBIQUE GRAN F N VR.K FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE[90-100]% by value / [90-100]% 
by volume
AC DE ASCORBIQUE GRAN F N VR.K FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE[90-100]% by value / [90-100]% 
by volume
AC DE ASCORBIQUE GRAN F N VR.K FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% 
by volume
AC DE ASCORBIQUE GRAN F N VR.K ITALYN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC 
ACID PARACETAMOL!PROPYPHENAZON E[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K FRANCE A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[60-70]% by value / [60-70]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K GERMANY 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S)[30-40]% by value / [10-20]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K GERMANY 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S)[30-40]% by value / [20-30]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K GERMANY 03C5 CONTACT LAXATIVES --> 03C5P POWDERS --> CITRIC AC D MAGNESIUM PICOSULFURIC AC D[50-60]% by value / [50-60]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K GERMANY A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)[30-40]% by value / [20-30]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K GERMANY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[40-50]% by value / [40-50]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K IRELAND 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K IRELAND A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K ITALY A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)[40-50]% by value / [30-40]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K ITALY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[70-80]% by value / [70-80]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K ITALY N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC[80-90]% by value / [80-90]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K POLAND A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[80-90]% by value / [80-90]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K PORTUGAL 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S)[30-40]% by value / [30-40]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K PORTUGAL A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)[70-80]% by value / [70-80]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K PORTUGAL A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE F BRE[70-80]% by value / [0-5]% by 
volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHAR DES + MALTODEXTRIN[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S)[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC 
ACID!GLUCOSE POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SPAIN A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
AC DE CITRIQUE ANH PDRE VR.K SWEDEN A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID[40-50]% by value / [40-50]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L BELGIUM 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L BELGIUM 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L BELGIUM A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID[70-80]% by value / [40-50]% by 
volumeCase M.10247 - CVC/Coope r
Downstream FDP Market (Recordati) Upstream Market (Target)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) 
AC DE PHOSPHORIQUE [80-90]%    VR.L BELGIUM A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> PHOSPHORIC AC D[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L FRANCE A12A CALCIUM --> A12A0 CALCIUM --> MAGNESIUM[50-60]% by value / [30-40]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L FRANCE A12A CALCIUM --> A12A0 CALCIUM --> PHOSPHORIC AC D[50-60]% by value / [30-40]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L FRANCE A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[50-60]% by value / [40-50]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L GERMANY 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L GERMANY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L ITALY 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2Q ENEMAS --> PHOSPHORIC ACID[30-40]% by value / [30-40]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L ITALY A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID[40-50]% by value / [10-20]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L NORWAY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L PORTUGAL 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L PORTUGAL A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
AC DE PHOSPHORIQUE [80-90]%    VR.L PORTUGAL A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[70-80]% by value / [70-80]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L SPAIN A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID[80-90]% by value / [80-90]% by 
volume
AC DE PHOSPHORIQUE [80-90]%    VR.L SPAIN A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[50-60]% by value / [50-60]% by 
volume
GLUCOSE ANH VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
GLUCOSE ANH VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
GLUCOSE ANH VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE[90-100]% by value / [90-100]% 
by volume
GLUCOSE ANH VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC 
ACID!GLUCOSE POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
GLUCOSE ANH VR.K SPAIN A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
GLUCOSE ANH VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> 
GLUCOSE!POTASSIUM!SODIUM!SUCROS E[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL MENTHOL!TALC!ZINC[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID[30-40]% by value / [30-40]% by 
volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PLANTAGO LANCEOLATA[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L CZECH REPUBLIC 06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA[30-40]% by value / [30-40]% by 
volume
GLYCERINE CONTA NER 1000 L FRANCE 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L FRANCE A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[50-60]% by value / [40-50]% by 
volume
GLYCERINE CONTA NER 1000 L FRANCE N7F DRUGS USED N OPIOID DEP --> N7F0 DRUGS USED N OPIOID DEP --> METHADONE[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L FRANCE R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL[90-100]% by value / [20-30]% 
by volume
GLYCERINE CONTA NER 1000 L FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L FRANCE R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L GERMANY 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L GERMANY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L NORWAY A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L PORTUGAL A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[70-80]% by value / [70-80]% by 
volume
GLYCERINE CONTA NER 1000 L SLOVAKIA 02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L SLOVAKIA 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> COMPOSITION UNKNOWN[80-90]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L SLOVAKIA 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID[50-60]% by value / [50-60]% by 
volume
GLYCERINE CONTA NER 1000 L SLOVAKIA 06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA[90-100]% by value / [90-100]% 
by volume
GLYCERINE CONTA NER 1000 L SPAIN A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID[50-60]% by value / [50-60]% by 
volume
ICHTHYOLAMMONIUM VR.K CZECH REPUBLIC06V1 OTHER SK N PRODUCTS --> 06V1O O NTMENTS/CREAMS --> 
ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI[90-100]% by value / [90-100]% 
by volume
ICHTHYOLAMMONIUM VR.K CZECH REPUBLICD5A TOP ANT PSORIASIS PRDS --> D5A0 TOP ANTIPSORIASIS PRDS --> 
ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K CZECH REPUBLIC C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K ITALY 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN[40-50]% by value / [40-50]% by 
volume
LIDOCAINE CHLTE VR.K ITALY M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
LIDOCAINE CHLTE VR.K LATVIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K LATVIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K LATVIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K LITHUANIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K POLAND 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[50-60]% by value / [60-70]% by 
volume
LIDOCAINE CHLTE VR.K POLAND 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K POLAND C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[70-80]% by value / [60-70]% by 
volume
LIDOCAINE CHLTE VR.K PORTUGAL 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K PORTUGAL C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K ROMANIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K ROMANIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K ROMANIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SLOVAKIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SPAIN 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> ALLANTOIN!AMINOACR DINE HYDROCORTISONE LIDOCA NE[90-100]% by value / [90-100]% 
by volume
LIDOCAINE CHLTE VR.K SPAINC5A TOPICAL ANT HAEMORRHOIDL --> C5A1 A-HAEMORRHO DL+CORTICOID --> 
ALLANTOIN!AMINOACR DINE!HYDROCORTISONE L DOCA N E[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K AUSTRIA G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K CZECH REPUBLIC G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volumeAt least EEA-wide <10%
MANNITOL VR.K FRANCE G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[30-40]% by value / [20-30]% by 
volume
MANNITOL VR.K GERMANY G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[60-70]% by value / [60-70]% by 
volume
MANNITOL VR.K GREECE G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K IRELAND G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K ITALY 04C3 PLAIN VITAMIN B --> 04C3M MIXTURES (ORAL) --> COBAMAMIDE[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K ITALY G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[60-70]% by value / [60-70]% by 
volume
MANNITOL VR.K POLAND G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K PORTUGAL G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[50-60]% by value / [40-50]% by 
volume
MANNITOL VR.K ROMANIA G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [90-100]% 
by volume
MANNITOL VR.K SLOVAKIA G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[90-100]% by value / [80-90]% 
by volume
MANNITOL VR.K SPAIN G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN[40-50]% by value / [40-50]% by 
volume
POTASSIUM CHLORURE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAINA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC 
ACID POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC 
ACID!GLUCOSE POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAIN A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
POTASSIUM CHLORURE VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> 
GLUCOSE!POTASSIUM!SODIUM!SUCROS E[90-100]% by value / [90-100]% 
by volume
SODIUM BICARBONATE VR.K SPAINA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC 
ACID POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K ITALY N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC[80-90]% by value / [80-90]% by 
volume
SODIUM CHLORURE VR.K ITALY R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUOCINOLONE ACETON DE[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAIN 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> COMPOSITION UNKNOWN[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAIN 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAINA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC 
ACID POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC 
ACID!GLUCOSE POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAIN A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM[90-100]% by value / [90-100]% 
by volume
SODIUM CHLORURE VR.K SPAINA7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM!SUCROS
E[90-100]% by value / [90-100]% 
by volume
SODIUM PHOSPHATE MONO PUR CRIST VK ITALY N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC[80-90]% by value / [80-90]% by 
volume
SODIUM PHOSPHATE MONO PUR CRIST VK SPAINA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC 
ACID POTASSIUM!SODIU M[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K CZECH REPUBLIC 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K CZECH REPUBLIC C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K ITALY 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN[40-50]% by value / [40-50]% by 
volume
SORBITOL VR K ITALY M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
SORBITOL VR K ITALY R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOL DE[40-50]% by value / [60-70]% by 
volume
SORBITOL VR K LATVIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K LATVIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K LATVIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K LITHUANIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K LITHUANIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K POLAND 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[50-60]% by value / [60-70]% by 
volume
SORBITOL VR K POLAND 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K POLAND C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[70-80]% by value / [60-70]% by 
volume
SORBITOL VR K PORTUGAL 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K PORTUGAL C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K ROMANIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K ROMANIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K ROMANIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K SLOVAKIA 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM[90-100]% by value / [90-100]% 
by volume
SORBITOL VR K SLOVAKIA C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE[90-100]% by value / [90-100]% 
by volume
Appendix 7.1
Upstream Hypothetical Market 
Segment (CDMO)Upstream 
Hypothetical 
Market Sub-
Segment (CDMO)Geographic Market Share (2020, EEA)Geographic 
MarketProduct Market (ATC3/CHC3) Share (2020)
A16A OTHER METABOLIC PRODUCTS <[0-5]% by value / [40-50]% by volume
S1X OTHER OPHTHALMOLOGICALS [80-90]% by value / [10-20]% by volume
DENMARK S1X OTHER OPHTHALMOLOGICALS Potentially up to [70-80]%ESTONIA H1C HYPOTHALAMIC HORMONES [40-50]% by value / [40-50]% by volumeFRANCE S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCT
S[70-80]% by value / [70-80]% by volume
H1C HYPOTHALAMIC HORMONES [30-40]% by value / [30-40]% by volumeS1X OTHER OPHTHALMOLOGICALS [50-60]% by value / [50-60]% by volume
HUNGARY B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeITALY S1X OTHER OPHTHALMOLOGICALS [40-50]% by value / [0-5]% by volumeNETHERLANDS S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [30-40]% by volume
PORTUGAL S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [70-80]% by volumeSPAIN B6X OTHER HAEMATOLOGICAL AGENTS [40-50]% by value / <[0-5]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [70-80]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volumeA16A OTHER METABOLIC PRODUCTS <[0-5]% by value / [40-50]% by volumeC8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
CYPRUS C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
A13A TONICS [70-80]% by value / [70-80]% by volumeS1K DRY EYE PRODUCTS [30-40]% by value / [30-40]% by volumeCase M.10247 - CVC/Cooper
Downstream FDP Market (Recordati)
CDMO services for FDPs -BELGIUM
GREECE
NORWAY
SWEDENUpstream Market (Target)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) 
BELGIUM
CZECH REPUBLI
C
C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volume
H1C HYPOTHALAMIC HORMONES [40-50]% by value / [40-50]% by volume
FINLAND C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volumeC8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [50-60]% by volume
GERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volume
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCT
S[70-80]% by value / [70-80]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [70-80]% by volumeH1C HYPOTHALAMIC HORMONES [30-40]% by value / [30-40]% by volume
HUNGARY C8B CALCIUM ANTAGONIST COMBS [40-50]% by value / [20-30]% by volumeICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeLITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volume
05A1 TONICS [70-80]%
A5B HEPATIC PROCT LIPOTROPIC [70-80]% by value / [50-60]% by volume
SLOVAKIA A13A TONICS [90-100]% by value / [90-100]% by volumeSPAIN C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumeSWEDEN C8B CALCIUM ANTAGONISTS, COMBINATIONS [40-50]% by value / [40-50]% by volumeCYPRUS C5A TOPICAL ANTI-HAEMORRHOIDALS [70-80]% by value / [80-90]% by volumeCZECH REPUBLI
CS1K DRY EYE PRODUCTS [30-40]% by value / [30-40]% by volume
FRANCE 83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volumeGREECE G1B GYNAECOLOG ANTIFUNGALS [60-70]% by value / [40-50]% by volumeHUNGARY G1B GYNAECOLOG ANTIFUNGALS [20-30]% by value / [60-70]% by volume
02D1 MOUTH PAIN RELIEF [30-40]%09C1 MOUTH INFECTION TREATMENT [10-20]% by value / [40-50]% by volume10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volumesolid and powder 
pharmaceuticals
PORTUGAL
ITALYESTONIA
FRANCE
GREECE
G4X ALL OTH UROLOGICAL PRODS [20-30]% by value / [40-50]% by volume
S2A ANTI-INFECTIVES - EAR [40-50]% by value / [10-20]% by volume
S2C STEROID/ANTI-INFECT-EAR [20-30]% by value / [30-40]% by volume
10A1 ANTIHAEMORRHOIDS [30-40]%
C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [20-30]% by volume
10A1 ANTIHAEMORRHOIDS [30-40]% by value / [30-40]% by volume
12D2 GYNAECOLOGICAL ANTIFUNGAL [80-90]% by value / [30-40]% by volume
C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volume
G1B GYNAECOLOG ANTIFUNGALS [50-60]% by value / [20-30]% by volume
10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volume
C5A TOPICAL ANTIHAEMORRHOIDL [50-60]% by value / [40-50]% by volume
G1B GYNAECOLOG ANTIFUNGALS [10-20]% by value / [30-40]% by volume
SLOVAKIA C5A TOPICAL ANTIHAEMORRHOIDL [20-30]% by value / [30-40]% by volume
03D3 ANTIDIARR ELECTROL [70-80]%
A7G ORAL ELECTROL. REPLACER [80-90]% by value / [90-100]% by volume
BELGIUM S1X OTHER OPHTHALMOLOGICALS [80-90]% by value / [10-20]% by volume
DENMARK S1X OTHER OPHTHALMOLOGICALS Potentially up to [70-80]%
ESTONIA C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volume
FRANCE S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
GERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volume
GREECE S1X OTHER OPHTHALMOLOGICALS [50-60]% by value / [50-60]% by volume
HUNGARY B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
ICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
ITALY S1X OTHER OPHTHALMOLOGICALS [40-50]% by value / [0-5]% by volume
LITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volume
NETHERLANDS S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volumeCDMO services for FDPs segmented 
by its pharmaceutical form, i e.
liquid and semi-solid pharmaceuticals
sterile liquid 
pharmaceuticalsLATVIA
POLAND
ROMANIA
SPAIN
B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [30-40]% by volume
PORTUGAL S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [70-80]% by volumeSPAIN B6X OTHER HAEMATOLOGICAL AGENTS [40-50]% by value / <[0-5]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [70-80]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
BELGIUM S1X OTHER OPHTHALMOLOGICALS [80-90]% by value / [10-20]% by volumeDENMARK S1X OTHER OPHTHALMOLOGICALS Potentially up to [70-80]%ESTONIA C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volumeFRANCE S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volumeGERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volumeGREECE S1X OTHER OPHTHALMOLOGICALS [50-60]% by value / [50-60]% by volumeHUNGARY B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeITALY S1X OTHER OPHTHALMOLOGICALS [40-50]% by value / [0-5]% by volumeLITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volumeNETHERLANDS S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [30-40]% by volume
PORTUGAL S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [70-80]% by volumeSPAIN B6X OTHER HAEMATOLOGICAL AGENTS [40-50]% by value / <[0-5]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [70-80]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
BELGIUM C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumeCYPRUS C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeESTONIA C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volumeCDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environmentNORWAY
SWEDEN
NORWAY
SWEDEN
FINLAND C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
FRANCE C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [50-60]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [70-80]% by volumeG1B GYNAECOLOG ANTIFUNGALS [60-70]% by value / [40-50]% by volumeC8B CALCIUM ANTAGONIST COMBS [40-50]% by value / [20-30]% by volumeG1B GYNAECOLOG ANTIFUNGALS [20-30]% by value / [60-70]% by volume
ICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeITALY G4X ALL OTH UROLOGICAL PRODS [20-30]% by value / [40-50]% by volumeLITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volume
12D2 GYNAECOLOGICAL ANTIFUNGAL [80-90]% by value / [30-40]% by volumeG1B GYNAECOLOG ANTIFUNGALS [50-60]% by value / [20-30]% by volume
ROMANIA G1B GYNAECOLOG ANTIFUNGALS [10-20]% by value / [30-40]% by volumeSPAIN C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumeSWEDEN C8B CALCIUM ANTAGONISTS, COMBINATIONS [40-50]% by value / [40-50]% by volume
A16A OTHER METABOLIC PRODUCTS <[0-5]% by value / [40-50]% by volumeC8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [80-90]% by value / [10-20]% by volumeC5A TOPICAL ANTI-HAEMORRHOIDALS [70-80]% by value / [80-90]% by volumeC7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeA13A TONICS [70-80]% by value / [70-80]% by volumeS1K DRY EYE PRODUCTS [30-40]% by value / [30-40]% by volume
DENMARK S1X OTHER OPHTHALMOLOGICALS Potentially up to [70-80]%
C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volumeH1C HYPOTHALAMIC HORMONES [40-50]% by value / [40-50]% by volume
FINLAND C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [50-60]% by volumenature of the 
technology/know-how needed to produce the FDPGREECE
HUNGARY
POLAND
BELGIUM
CYPRUS
CZECH REPUBLI
C
ESTONIA
FRANCE
S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
GERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volume
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCT S[70-80]% by value / [70-80]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [70-80]% by volumeG1B GYNAECOLOG ANTIFUNGALS [60-70]% by value / [40-50]% by volumeH1C HYPOTHALAMIC HORMONES [30-40]% by value / [30-40]% by volumeS1X OTHER OPHTHALMOLOGICALS [50-60]% by value / [50-60]% by volumeC8B CALCIUM ANTAGONIST COMBS [40-50]% by value / [20-30]% by volumeG1B GYNAECOLOG ANTIFUNGALS [20-30]% by value / [60-70]% by volume
ICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
02D1 MOUTH PAIN RELIEF [30-40]%09C1 MOUTH INFECTION TREATMENT [10-20]% by value / [40-50]% by volume10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volumeG4X ALL OTH UROLOGICAL PRODS [20-30]% by value / [40-50]% by volumeS1X OTHER OPHTHALMOLOGICALS [40-50]% by value / [0-5]% by volumeS2A ANTI-INFECTIVES - EAR [40-50]% by value / [10-20]% by volumeS2C STEROID/ANTI-INFECT-EAR [20-30]% by value / [30-40]% by volume10A1 ANTIHAEMORRHOIDS [30-40]%C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [20-30]% by volume
LITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volumeNETHERLANDS S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volumeNORWAY S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [30-40]% by volume
10A1 ANTIHAEMORRHOIDS [30-40]% by value / [30-40]% by volume12D2 GYNAECOLOGICAL ANTIFUNGAL [80-90]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volumeCDMO services for FDPs segmented 
by the type of API used, i.e.At least EEA-wide <[10-20]%
chemically-
synthesized APIs
FRANCE
GREECE
HUNGARY
ITALY
LATVIA
POLAND
G1B GYNAECOLOG ANTIFUNGALS [50-60]% by value / [20-30]% by volume
05A1 TONICS [70-80]%
A5B HEPATIC PROCT LIPOTROPIC [70-80]% by value / [50-60]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [70-80]% by volume10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [50-60]% by value / [40-50]% by volumeG1B GYNAECOLOG ANTIFUNGALS [10-20]% by value / [30-40]% by volumeA13A TONICS [90-100]% by value / [90-100]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [20-30]% by value / [30-40]% by volume
SPAIN C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
C8B CALCIUM ANTAGONISTS, COMBINATIONS [40-50]% by value / [40-50]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
FRANCE 83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volumeHUNGARY B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeNORWAY B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volume
03D3 ANTIDIARR ELECTROL [70-80]%A7G ORAL ELECTROL. REPLACER [80-90]% by value / [90-100]% by volumeB6X OTHER HAEMATOLOGICAL AGENTS [40-50]% by value / <[0-5]% by volume
SWEDEN B6X OTHER HAEMATOLOGICAL AGENTS [70-80]% by value / [90-100]% by volume
A16A OTHER METABOLIC PRODUCTS <[0-5]% by value / [40-50]% by volumeC8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
CYPRUS C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
A13A TONICS [70-80]% by value / [70-80]% by volumeS1K DRY EYE PRODUCTS [30-40]% by value / [30-40]% by volume
ESTONIA C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volumeFINLAND C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumebiopharmaceutical 
APIsPORTUGAL
ROMANIA
SLOVAKIA
SWEDEN
SPAIN
BELGIUM
CZECH REPUBLI
C
83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [50-60]% by volume
GERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volume
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCT S[70-80]% by value / [70-80]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [70-80]% by volume
HUNGARY C8B CALCIUM ANTAGONIST COMBS [40-50]% by value / [20-30]% by volume
ICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
ITALY 09C1 MOUTH INFECTION TREATMENT [10-20]% by value / [40-50]% by volume
LITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volume
05A1 TONICS [70-80]%
A5B HEPATIC PROCT LIPOTROPIC [70-80]% by value / [50-60]% by volume
SLOVAKIA A13A TONICS [90-100]% by value / [90-100]% by volume
03D3 ANTIDIARR ELECTROL [70-80]%
A7G ORAL ELECTROL. REPLACER [80-90]% by value / [90-100]% by volume
C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
SWEDEN C8B CALCIUM ANTAGONISTS, COMBINATIONS [40-50]% by value / [40-50]% by volume
CYPRUS C5A TOPICAL ANTI-HAEMORRHOIDALS [70-80]% by value / [80-90]% by volume
FRANCE 83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volume
GREECE G1B GYNAECOLOG ANTIFUNGALS [60-70]% by value / [40-50]% by volume
02D1 MOUTH PAIN RELIEF [30-40]%
G4X ALL OTH UROLOGICAL PRODS [20-30]% by value / [40-50]% by volume
10A1 ANTIHAEMORRHOIDS [30-40]%
C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [20-30]% by volume
10A1 ANTIHAEMORRHOIDS [30-40]% by value / [30-40]% by volume
C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volume
10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeCDMO services for FDPs segmented 
by the delivery mechanism used, i e.
absorption through the skinswallowingFRANCE
GREECE
PORTUGAL
SPAIN
ITALY
LATVIAPOLAND
C5A TOPICAL ANTIHAEMORRHOIDL [50-60]% by value / [40-50]% by volume
G1B GYNAECOLOG ANTIFUNGALS [10-20]% by value / [30-40]% by volume
SLOVAKIA C5A TOPICAL ANTIHAEMORRHOIDL [20-30]% by value / [30-40]% by volume
C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [80-90]% by value / [10-20]% by volumeC5A TOPICAL ANTI-HAEMORRHOIDALS [70-80]% by value / [80-90]% by volumeC7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volumeA13A TONICS [70-80]% by value / [70-80]% by volumeS1K DRY EYE PRODUCTS [30-40]% by value / [30-40]% by volume
DENMARK S1X OTHER OPHTHALMOLOGICALS Potentially up to [70-80]%ESTONIA C7A B-BLOCKING AGENTS,PLAIN [40-50]% by value / [30-40]% by volumeFINLAND C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
83E1 LEG CARE PRODUCTS [50-60]% by value / [50-60]% by volumeC8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [50-60]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
GERMANY M3B MUSCLE RELAXANTS,CENTRAL [40-50]% by value / [20-30]% by volume
C8B CALCIUM ANTAGONIST COMBS [70-80]% by value / [70-80]% by volumeG1B GYNAECOLOG ANTIFUNGALS [60-70]% by value / [40-50]% by volumeS1X OTHER OPHTHALMOLOGICALS [50-60]% by value / [50-60]% by volumeB6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeC8B CALCIUM ANTAGONIST COMBS [40-50]% by value / [20-30]% by volumeG1B GYNAECOLOG ANTIFUNGALS [20-30]% by value / [60-70]% by volume
ICELAND C7A BETA-BLOCKING AGENTS, PLAIN [30-40]% by value / [20-30]% by volume
02D1 MOUTH PAIN RELIEF [30-40]%09C1 MOUTH INFECTION TREATMENT [10-20]% by value / [40-50]% by volume10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeROMANIA
BELGIUM
CYPRUSCZECH REPUBLI
C
FRANCE
GREECE
HUNGARY
C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volume
G4X ALL OTH UROLOGICAL PRODS [20-30]% by value / [40-50]% by volumeS1X OTHER OPHTHALMOLOGICALS [40-50]% by value / [0-5]% by volumeS2A ANTI-INFECTIVES - EAR [40-50]% by value / [10-20]% by volumeS2C STEROID/ANTI-INFECT-EAR [20-30]% by value / [30-40]% by volume10A1 ANTIHAEMORRHOIDS [30-40]%C5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [20-30]% by volume
LITHUANIA C7A B-BLOCKING AGENTS,PLAIN [30-40]% by value / [30-40]% by volumeNETHERLANDS S1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [90-100]% by value / [90-100]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [30-40]% by volume10A1 ANTIHAEMORRHOIDS [30-40]% by value / [30-40]% by volume12D2 GYNAECOLOGICAL ANTIFUNGAL [80-90]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [30-40]% by value / [30-40]% by volumeG1B GYNAECOLOG ANTIFUNGALS [50-60]% by value / [20-30]% by volume05A1 TONICS [70-80]%
A5B HEPATIC PROCT LIPOTROPIC [70-80]% by value / [50-60]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [70-80]% by volume10A1 ANTIHAEMORRHOIDS [20-30]% by value / [30-40]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [50-60]% by value / [40-50]% by volumeG1B GYNAECOLOG ANTIFUNGALS [10-20]% by value / [30-40]% by volumeA13A TONICS [90-100]% by value / [90-100]% by volumeC5A TOPICAL ANTIHAEMORRHOIDL [20-30]% by value / [30-40]% by volume03D3 ANTIDIARR ELECTROL [70-80]%A7G ORAL ELECTROL. REPLACER [80-90]% by value / [90-100]% by volumeB6X OTHER HAEMATOLOGICAL AGENTS [40-50]% by value / <[0-5]% by volumeCMO services (excluding CDO 
services)-
ROMANIA
SLOVAKIA
SPAINITALY
LATVIA
NORWAY
POLAND
PORTUGAL
C8B CALCIUM ANTAGONIST COMBS [90-100]% by value / [90-100]% by volume
B6X OTHER HAEMATOLOGICAL AGENTS [70-80]% by value / [90-100]% by volumeC8B CALCIUM ANTAGONISTS, COMBINATIONS [40-50]% by value / [40-50]% by volumeS1X OTHER OPHTHALMOLOGICALS [90-100]% by value / [90-100]% by volumeSWEDEN
Appendix 7.1
Upstream Hypothetical Market 
Segment (CDMO )Upstream Hypothetical Market Sub -
Segment (CDMO )Geographic 
MarketShare (2020, EE AGeographic 
MarketProduct Market (ATC4/CHC4) Share (2020)
CDMO services for FDPs - AUSTRIA A11X3 VITAMIN E PLAIN[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs - BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs - FRANCE A11X3 VITAMIN E PLAIN[30-40]% by value / <[0-5]% by 
volume
CDMO services for FDPs - FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALY 30C1Z OTHER MODULES[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs - ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs - NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs - PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs - SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.solid and powder pharmaceuticals BELGIUM C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals FINLAND C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals FRANCE 01A4E EFFERVESCENT[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals FRANCE 01A4P POWDERS[30-40]% by value / [40-50]% by 
volumeCase M.10247 - CVC/Cooper
Downstream FDP Market (Recordati)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream)
Upstream Market (Target)
At leat EEA-wide <1[0-5]%
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.solid and powder pharmaceuticals FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals FRANCE C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals GREECE C8B2 CALC ANTAG/B BLOCKR COMB[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals HUNGARY C8B2 CALC ANTAG/B BLOCKR COMB[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals ITALY A7E9 INFLAM BOWEL DIS PRD OTH<[0-5]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals PORTUGAL 03C4Q ENEMAS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals PORTUGAL 03F1M MIXTURES (ORAL)[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals PORTUGAL 05A1Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals PORTUGAL A2B9 ALL OTHER ANTIULCERANTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals PORTUGAL A6A4 LAXATIVE ENEMAS[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals ROMANIA 03C1Z OTHER FORMS[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals SPAIN 03C1Z OTHER FORMS[60-70]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals SPAIN 03F1M MIXTURES (ORAL)[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.solid and powder pharmaceuticals SPAIN C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals AUSTRIA A11X3 VITAMIN E PLAIN[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals FRANCE 01A9Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals FRANCE A11X3 VITAMIN E PLAIN[30-40]% by value / <[0-5]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 02D1O OINTMENTS/CREAMS[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 02D1Z OTHER FORMS[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 02E1L LIQUIDS (TOPICAL)[60-70]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 09C1G RINSES/GARGLES[10-20]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 10A1O OINTMENTS/CREAMS[20-30]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY 30C1Z OTHER MODULES[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY C5A1 A-HAEMORRHOIDL+CORTICOID[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals POLAND 12D2S SUPPOSITORIES[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals PORTUGAL 02D1O OINTMENTS/CREAMS[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals PORTUGAL 03F1M MIXTURES (ORAL)[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals PORTUGAL A2B9 ALL OTHER ANTIULCERANTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals PORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals SPAIN 03F1M MIXTURES (ORAL)[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals SPAIN G4E9 ERECTILE DYSFUNC PRD OTH[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.liquid and semi-solid pharmaceuticals SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceuticals BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceuticals FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals ITALY S1G1 OCUL.A-ALLERG ANTIHIST.[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.sterile liquid pharmaceu icals SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsLATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsLATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsLATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsLITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsPORTUGAL 02E1K NON HEAT/COLD PATCHES[60-70]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsSLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by its pharmaceutical form, i e.medicated confectionary pharmaceuticalsSLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment ITALY S1G1 OCUL.A-ALLERG ANTIHIST.[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.sterile environment SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPBELGIUM C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPBELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce he FDPFINLAND C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce he FDPFRANCE C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce he FDPFRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPGREECE C8B2 CALC ANTAG/B BLOCKR COMB[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPHUNGARY C8B2 CALC ANTAG/B BLOCKR COMB[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPNETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPNORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPPOLAND 12D2S SUPPOSITORIES[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPPORTUGAL 02E1K NON HEAT/COLD PATCHES[60-70]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPPORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPPORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPSPAIN C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPSPAIN G4E9 ERECTILE DYSFUNC PRD OTH[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the conditions of manufacture, i.e.nature of the technology/know-how needed to produce the FDPSWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs AUSTRIA A11X3 VITAMIN E PLAIN[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs BELGIUM C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FINLAND C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-syn hesized APIs FRANCE 01A4E EFFERVESCENT[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FRANCE 01A4P POWDERS[30-40]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FRANCE 01A9Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FRANCE A11X3 VITAMIN E PLAIN[30-40]% by value / <[0-5]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FRANCE C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs GREECE C8B2 CALC ANTAG/B BLOCKR COMB[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs HUNGARY C8B2 CALC ANTAG/B BLOCKR COMB[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 02D1O OINTMENTS/CREAMS[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 02D1Z OTHER FORMS[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 02E1L LIQUIDS (TOPICAL)[60-70]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 09C1G RINSES/GARGLES[10-20]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 10A1O OINTMENTS/CREAMS[20-30]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY 30C1Z OTHER MODULES[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY A7E9 INFLAM BOWEL DIS PRD OTH<[0-5]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY C5A1 A-HAEMORRHOIDL+CORTICOID[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-syn hesized APIs ITALY S1G1 OCUL.A-ALLERG ANTIHIST.[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs POLAND 12D2S SUPPOSITORIES[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL 02D1O OINTMENTS/CREAMS[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL 02E1K NON HEAT/COLD PATCHES[60-70]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL 03C4Q ENEMAS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL 05A1Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL A2B9 ALL OTHER ANTIULCERANTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL A6A4 LAXATIVE ENEMAS[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ROMANIA 03C1Z OTHER FORMS[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SPAIN 03C1Z OTHER FORMS[60-70]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SPAIN C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SPAIN G4E9 ERECTILE DYSFUNC PRD OTH[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-syn hesized APIs SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.biopharmaceutical APIs FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.biopharmaceutical APIs PORTUGAL 03F1M MIXTURES (ORAL)[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.biopharmaceutical APIs SPAIN 03F1M MIXTURES (ORAL)[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIA A11X3 VITAMIN E PLAIN[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUM C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FINLAND C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE 01A4E EFFERVESCENT[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE 01A4P POWDERS[30-40]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE 01A9Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE A11X3 VITAMIN E PLAIN[30-40]% by value / <[0-5]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GREECE C8B2 CALC ANTAG/B BLOCKR COMB[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing HUNGARY C8B2 CALC ANTAG/B BLOCKR COMB[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY 09C1G RINSES/GARGLES[10-20]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY 30C1Z OTHER MODULES[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY A7E9 INFLAM BOWEL DIS PRD OTH<[0-5]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL 03C4Q ENEMAS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL 03F1M MIXTURES (ORAL)[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL 05A1Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL A2B9 ALL OTHER ANTIULCERANTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL A6A4 LAXATIVE ENEMAS[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ROMANIA 03C1Z OTHER FORMS[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN 03C1Z OTHER FORMS[60-70]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN 03F1M MIXTURES (ORAL)[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin ITALY 02D1O OINTMENTS/CREAMS[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin ITALY 02D1Z OTHER FORMS[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin ITALY 02E1L LIQUIDS (TOPICAL)[60-70]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin PORTUGAL 02D1O OINTMENTS/CREAMS[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through the skin SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- BELGIUM C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- BELGIUM S1X2 OTH OPHTHALM TOPICAL[80-90]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- FINLAND C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE 01A4E EFFERVESCENT[20-30]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- FRANCE 01A4P POWDERS[30-40]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- FRANCE 01A9Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE 83E1 LEG CARE PRODUCTS[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- FRANCE C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- FRANCE S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECE C8B2 CALC ANTAG/B BLOCKR COMB[70-80]% by value / [70-80]% by 
volume
CMO services (excluding CDO services)- HUNGARY C8B2 CALC ANTAG/B BLOCKR COMB[50-60]% by value / [40-50]% by 
volume
CMO services (excluding CDO services)- ITALY 02D1O OINTMENTS/CREAMS[50-60]% by value / [40-50]% by 
volume
CMO services (excluding CDO services)- ITALY 02D1Z OTHER FORMS[40-50]% by value / [40-50]% by 
volume
CMO services (excluding CDO services)- ITALY 02E1L LIQUIDS (TOPICAL)[60-70]% by value / [10-20]% by 
volume
CMO services (excluding CDO services)- ITALY 09C1G RINSES/GARGLES[10-20]% by value / [40-50]% by 
volume
CMO services (excluding CDO services)- ITALY 10A1O OINTMENTS/CREAMS[20-30]% by value / [40-50]% by 
volume
CMO services (excluding CDO services)- ITALY A7E9 INFLAM BOWEL DIS PRD OTH<[0-5]% by value / [90-100]% by 
volume
CMO services (excluding CDO services)- ITALY C5A1 A-HAEMORRHOIDL+CORTICOID[50-60]% by value / [60-70]% by 
volume
CMO services (excluding CDO services)- ITALY S1G1 OCUL.A-ALLERG ANTIHIST.[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO services)- ITALY S1X2 OTH OPHTHALM TOPICAL[40-50]% by value / [0-5]% by 
volume
CMO services (excluding CDO services)- LATVIA 10A1O OINTMENTS/CREAMS[40-50]% by value / [30-40]% by 
volume
CMO services (excluding CDO services)- LATVIA 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO services)- LATVIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO services)- LITHUANIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO services)- NETHERLANDS S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NORWAY S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- POLAND 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- POLAND 10A1S SUPPOSITORIES[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- POLAND 12D2S SUPPOSITORIES[90-100]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- POLAND C5A2 A-HAEMORRHOID W/O CORTIC[40-50]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 02D1O OINTMENTS/CREAMS[30-40]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 02E1K NON HEAT/COLD PATCHES[60-70]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 03C4Q ENEMAS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 03F1M MIXTURES (ORAL)[50-60]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 05A1Z OTHER FORMS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL A2B9 ALL OTHER ANTIULCERANTS[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL A6A4 LAXATIVE ENEMAS[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL G4E9 ERECTILE DYSFUNC PRD OTH[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA 03C1Z OTHER FORMS[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA 10A1O OINTMENTS/CREAMS[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA C5A2 A-HAEMORRHOID W/O CORTIC[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA 10A1S SUPPOSITORIES[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA C5A2 A-HAEMORRHOID W/O CORTIC[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- SPAIN 03C1Z OTHER FORMS[60-70]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- SPAIN 03F1M MIXTURES (ORAL)[40-50]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- SPAIN C8B2 CALC ANTAG/B BLOCKR COMB[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN G4E9 ERECTILE DYSFUNC PRD OTH[40-50]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- SWEDEN S1X2 OTH OPHTHALM TOPICAL[90-100]% by value / [90-100]% by 
volume
Appendix 7.1
Upstream Hypothetical Market 
Segment (CDMO)Upstream 
Hypothetical 
Market Sub-
Segment (CDMO )Geographic 
Marketare (2020, E EGeographic 
MarketMolecule-level Category Share (2020)
CDMO services for FDPs - AUSTRIAA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - AUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - AUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volumeCase M.10247 - CVC/Cooper
Downstream FDP Market (Recordati) Upstream Market (Target)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) 
CDMO services for FDPs - BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [60-70]% by 
volume
CDMO services for FDPs - BELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs - FRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCEL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - FRANCE V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[5-10]% by value / [30-40]% by 
volume
CDMO services for FDPs - GERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYK4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> 
HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs - HUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs - ITALYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs - ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYB1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. -
-> ARGATROBAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - ITALY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs - NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - NORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - PORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SPAINA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs - SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[30-40]% by value / [80-90]% by 
volume
CDMO services for FDPs - SPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SPAIN V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SWEDENA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs - SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [70-80]% by 
volume
CDMO services for FDPs - SWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs - SWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBELGIUMC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBULGARIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsBULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
ASCORBIC ACID!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLICG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFINLANDC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> 
ACETYLCYSTEINE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> 
ACETYLCYSTEINE[30-40]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS 
HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEA6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W 
ELECTRO --> MACROGOL(S)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> 
MACROGOL(S)!POTASSIUM!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCEJ1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR 
TYPE --> ERYTHROMYCIN[10-20]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BENZOIC ACID!BROMINE!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BROMOFORM!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> 
CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsFRANCE V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO 
OVATA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> 
CALCIUM!MAGNESIUM!POTASSIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[5-10]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGREECEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsGREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsHUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsHUNGARYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> 
TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> 
DIMETHYL SULFONE[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> 
DIMETHYL SULFONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ARGININE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
LYSINE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> 
INOSITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> 
PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> 
DIOSCOREA VILLOSA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
DOMPERIDONE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST 
CORTICOSTER PROD --> BUDESONIDE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM 
BOWEL DIS PRD OTH --> CROMOGLICIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYA9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES - -
> TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYC10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA 
RED) --> LOVASTATIN[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYC1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC 
PREPS --> ALPROSTADIL ALFADEX[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYC4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB 
ACTIV --> CINNARIZINE[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> BISOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYJ1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --
> CEFTIBUTEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYJ1D CEPHALOSPORINS & COMBS --> J1D2 
CEPHALOSPORINS,PARENT. --> CEFODIZIME[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALYR6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES 
SYSTEMIC --> RUPATADINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsITALY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsLATVIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsLITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsLITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsLUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNETHERLANDSN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsNORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPOLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM 
OFFICINALE[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC 
ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC 
ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> 
COLECALCIFEROL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> 
SUCRALFATE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT 
LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALA6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> 
CITRIC ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALC9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC 
ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> DEXIBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALM4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT 
PREPARATIONS --> COLCHICINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
SISYMBRIUM OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsPORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
INULIN!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIA04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> 
CALCIUM!COLECALCIFEROL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIAC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> DIOSMIN[80-90]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIAG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID!ASCORBIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSLOVAKIAS1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS 
SALIVARIUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[30-40]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
CINITAPRIDE[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAINN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSPAIN V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.solid and powder 
pharmaceuticalsSWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsAUSTRIAA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsAUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsAUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsBELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsBELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsBULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
ASCORBIC ACID!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLICC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsCZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> 
CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
SODIUM[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC 
ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCE87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED 
GUM&G --> COMPOSITION UNKNOWN[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCEL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsFRANCES2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
RIFAMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-
PROPANOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-
PROPANOL[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC[50-60]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> 
SALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> 
LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> 
MENTHA ARVENSIS[70-80]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> ZINC[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYH2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN - -
> DEXAMETHASONE[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> 2-PROPANOL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGERMANYV3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL 
PREPARATIONS --> MENTHA ARVENSIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsGREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsHUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsHUNGARYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [5-10]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZETHONIUM CHLORIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> 
DICLOFENAC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 
NAPROXEN[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC 
MEDICINES[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> 
HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!SODIUM!TROMETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> 
EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
COMPOSITION UNKNOWN[60-70]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> 
PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> 
BORAGO OFFICINALIS[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH 
--> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
DOMPERIDONE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYB1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. -
-> ARGATROBAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYC4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB 
ACTIV --> CINNARIZINE[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYC5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYR1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> 
BUDESONIDE[60-70]% by value / [60-70]% by 
volume (CVC share [70-80]% by 
value / [70-80]% by volume)
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE[60-70]% by value / [50-60]% by 
volume (CVC share [60-70]% by 
value / [60-70]% by volume)
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYR6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES 
SYSTEMIC --> RUPATADINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYS2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
CIPROFLOXACIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsITALYS2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR - -
> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLATVIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLITHUANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsLUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsNORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLANDC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPOLANDG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> 
COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGAL10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGALA2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> 
SUCRALFATE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGALC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGALG4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsPORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE 
+ TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSLOVAKIAS1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> COMPOSITION UNKNOWN[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> DIMETICONE!JOJOBA OIL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAINA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAINA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
CINITAPRIDE[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAING4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSPAING4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSWEDENA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.liquid and semi-solid 
pharmaceuticalsSWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsAUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsAUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsBELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsBELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsCZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsFRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYH2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN - -
> DEXAMETHASONE[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYK4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> 
HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> PHENYLBUTAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsGERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsHUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsHUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALY07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> 
NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!SODIUM!TROMETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALY07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> 
EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALYS1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-
ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsLITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsLUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsNORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsPOLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsPORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.sterile liquid 
pharmaceuticalsSWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsCZECH 
REPUBLICC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC 
ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCE87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED 
GUM&G --> COMPOSITION UNKNOWN[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsGERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsGERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC[50-60]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> ZINC[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsITALY03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC 
MEDICINES[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsITALY87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH 
--> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLATVIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsLITHUANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGAL01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGAL02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGALA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> 
COLECALCIFEROL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGALM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsPORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE 
+ TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsROMANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by its pharmaceutical form, i.e.medicated 
confectionary pharmaceuticalsSLOVAKIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCEJ1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR 
TYPE --> ERYTHROMYCIN[10-20]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BENZOIC ACID!BROMINE!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BROMOFORM!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> 
CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity FRANCES2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
RIFAMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity GERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity GERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity ITALYJ1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --
> CEFTIBUTEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity ITALYJ1D CEPHALOSPORINS & COMBS --> J1D2 
CEPHALOSPORINS,PARENT. --> CEFODIZIME[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.toxicity ITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment AUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment AUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment BELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environmentCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment FRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment FRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment FRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment FRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYH2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN - -
> DEXAMETHASONE[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYK4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> 
HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> PHENYLBUTAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment GERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment HUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment HUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALY07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> 
NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYC1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC 
PREPS --> ALPROSTADIL ALFADEX[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYJ1D CEPHALOSPORINS & COMBS --> J1D2 
CEPHALOSPORINS,PARENT. --> CEFODIZIME[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYS1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-
ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment ITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment LITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment NORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment POLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment PORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment SLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment SPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment SWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment SWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.sterile environment SWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPAUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPBELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPBELGIUMC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPBELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPBULGARIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPBULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPCZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFINLANDC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFRANCEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPFRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANY12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> 
LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANYG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGREECEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPGREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPHUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPHUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPHUNGARYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPHUNGARYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [5-10]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYR1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> 
BUDESONIDE[60-70]% by value / [60-70]% by 
volume (CVC share [70-80]% by 
value / [70-80]% by volume)
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE[60-70]% by value / [50-60]% by 
volume (CVC share [60-70]% by 
value / [60-70]% by volume)
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPLATVIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPLITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPLITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPLUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPNETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPNETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPNORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPNORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPNORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPOLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPOLANDG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPORTUGAL02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPORTUGALG4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPORTUGALM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPPORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSPAINC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSPAINC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSPAING4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSPAING4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the conditions of manufacture, i.e.nature of the 
technology/know-how needed to produce the FDPSWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsAUSTRIAA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsAUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsAUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBULGARIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsBULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
ASCORBIC ACID!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFINLANDC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> 
ACETYLCYSTEINE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> 
ACETYLCYSTEINE[30-40]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> 
CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
SODIUM[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC 
ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED 
GUM&G --> COMPOSITION UNKNOWN[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W 
ELECTRO --> MACROGOL(S)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> 
MACROGOL(S)!POTASSIUM!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEJ1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR 
TYPE --> ERYTHROMYCIN[10-20]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCEL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BENZOIC ACID!BROMINE!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BROMOFORM!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> 
CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCES2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
RIFAMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsFRANCE V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-
PROPANOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-
PROPANOL[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> 
CALCIUM!MAGNESIUM!POTASSIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC[50-60]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> 
SALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> 
LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> 
MENTHA ARVENSIS[70-80]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[5-10]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> ZINC[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYH2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN - -
> DEXAMETHASONE[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> PHENYLBUTAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> 2-PROPANOL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGERMANYV3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL 
PREPARATIONS --> MENTHA ARVENSIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGREECEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsGREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsHUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsHUNGARYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsHUNGARYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [5-10]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZETHONIUM CHLORIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> 
DICLOFENAC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 
NAPROXEN[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC 
MEDICINES[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> 
DIMETHYL SULFONE[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> 
DIMETHYL SULFONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ARGININE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
LYSINE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> 
INOSITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-synthesized APIsITALY06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!SODIUM!TROMETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIsITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> COMPOSITION UNKNOWN[60-70]% by value / [80-90]% by 
volumeAt least EEA
wide<[10-20]%
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH 
--> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
DOMPERIDONE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST 
CORTICOSTER PROD --> BUDESONIDE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM 
BOWEL DIS PRD OTH --> CROMOGLICIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYA7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYB1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. -
-> ARGATROBAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA 
RED) --> LOVASTATIN[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC 
PREPS --> ALPROSTADIL ALFADEX[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB 
ACTIV --> CINNARIZINE[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> BISOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYJ1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --
> CEFTIBUTEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYJ1D CEPHALOSPORINS & COMBS --> J1D2 
CEPHALOSPORINS,PARENT. --> CEFODIZIME[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYR1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> 
BUDESONIDE[60-70]% by value / [60-70]% by 
volume (CVC share [70-80]% by 
value / [70-80]% by volume)
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE[60-70]% by value / [50-60]% by 
volume (CVC share [60-70]% by 
value / [60-70]% by volume)
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYR6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES 
SYSTEMIC --> RUPATADINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYS1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-
ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYS2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
CIPROFLOXACIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALYS2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR - -
> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsITALY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLATVIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLATVIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLITHUANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsLUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNORWAYH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsNORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPOLANDG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC 
ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC 
ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> 
COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> 
COLECALCIFEROL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> 
SUCRALFATE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT 
LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALA6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> 
CITRIC ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALC9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC 
ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALG4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> DEXIBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALM4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT 
PREPARATIONS --> COLCHICINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsPORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
INULIN!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> 
CALCIUM!COLECALCIFEROL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE 
+ TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIAC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> DIOSMIN[80-90]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIAG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID!ASCORBIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSLOVAKIAS1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[30-40]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
CINITAPRIDE[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAING4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAING4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAINN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSPAIN V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENH1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES 
--> PASIREOTIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.chemically-
synthesized APIsSWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsAUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS 
HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsFRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANY03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO 
OVATA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANYK4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> 
HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsGERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsHUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> 
TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> 
PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> 
DIOSCOREA VILLOSA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> 
BORAGO OFFICINALIS[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALY
A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES - -
> TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsNETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsNORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGAL01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM 
OFFICINALE[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsPORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
SISYMBRIUM OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAIN08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS 
SALIVARIUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the type of API used, i.e.biopharmaceutical 
APIsSWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIAA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing AUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUMA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BELGIUMC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing BULGARIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
ASCORBIC ACID!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLICG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowingCZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FINLANDC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> 
ACETYLCYSTEINE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> 
ACETYLCYSTEINE[30-40]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> 
CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC 
ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS 
HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED 
GUM&G --> COMPOSITION UNKNOWN[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W 
ELECTRO --> MACROGOL(S)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> 
MACROGOL(S)!POTASSIUM!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCEJ1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR 
TYPE --> ERYTHROMYCIN[10-20]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BENZOIC ACID!BROMINE!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BROMOFORM!CODEINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> 
CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCES2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
RIFAMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing FRANCE V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO 
OVATA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> 
CALCIUM!MAGNESIUM!POTASSIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[5-10]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GERMANY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing GREECEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing HUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing HUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing HUNGARYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing IRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> 
TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED)[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC 
MEDICINES[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> 
DIMETHYL SULFONE[50-60]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> 
DIMETHYL SULFONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ARGININE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
LYSINE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
COMPOSITION UNKNOWN[60-70]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> 
PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> 
DIOSCOREA VILLOSA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> 
BORAGO OFFICINALIS[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH 
--> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
DOMPERIDONE[60-70]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST 
CORTICOSTER PROD --> BUDESONIDE[20-30]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM 
BOWEL DIS PRD OTH --> CROMOGLICIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYA9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES - -
> TILACTASE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYC10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA 
RED) --> LOVASTATIN[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYC4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB 
ACTIV --> CINNARIZINE[40-50]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> BISOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYJ1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --
> CEFTIBUTEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYL1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. 
ANTIBIOTICS --> DACTINOMYCIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALYR6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES 
SYSTEMIC --> RUPATADINE[30-40]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ITALY V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing LATVIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing LITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing LUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NETHERLANDSN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NORWAYA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing NORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN!MENTHOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLANDA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing POLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM 
OFFICINALE[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC 
ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC 
ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> 
COLECALCIFEROL[30-40]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> 
SUCRALFATE[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT 
LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALA6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> 
CITRIC ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALC9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC 
ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> DEXIBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALM4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT 
PREPARATIONS --> COLCHICINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
SISYMBRIUM OFFICINALE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing PORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
INULIN!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ROMANIA04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> 
CALCIUM!COLECALCIFEROL[30-40]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing ROMANIAC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> DIOSMIN[80-90]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID!ASCORBIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN[70-80]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SLOVAKIAS1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE[70-80]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS 
SALIVARIUS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[30-40]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
CINITAPRIDE[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAINN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SPAIN V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SWEDENA11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> 
TOCOFERSOLAN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> BETAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> CARGLUMIC ACID[70-80]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SWEDENA16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC 
PRODUCTS --> MERCAPTAMINE[10-20]% by value / [70-80]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.swallowing SWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.inhalation FRANCE01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
SODIUM[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.inhalation ITALY01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.inhalation ITALYR1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> 
BUDESONIDE[60-70]% by value / [60-70]% by 
volume (CVC share [70-80]% by 
value / [70-80]% by volume)
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.inhalation ITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE[60-70]% by value / [50-60]% by 
volume (CVC share [60-70]% by 
value / [60-70]% by volume)
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinBULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLICC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinCZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinFRANCEL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-
PROPANOL[60-70]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-
PROPANOL[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC[50-60]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> 
SALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> 
LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> 
MENTHA ARVENSIS[70-80]% by value / [20-30]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> ZINC[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [0-5]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> 2-PROPANOL[50-60]% by value / [50-60]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGERMANYV3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL 
PREPARATIONS --> MENTHA ARVENSIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinGREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinIRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [5-10]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZETHONIUM CHLORIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> 
DICLOFENAC[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 
NAPROXEN[40-50]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> 
HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALYL1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> 
CHLORMETHINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLATVIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLATVIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLITHUANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinLITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[50-60]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPOLAND10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPOLANDC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[70-80]% by value / [60-70]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> 
COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGAL10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinPORTUGALC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE 
+ TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSLOVAKIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> COMPOSITION UNKNOWN[40-50]% by value / [10-20]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> DIMETICONE!JOJOBA OIL[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.absorption through 
the skinSPAING4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.intravenous injection AUSTRIAC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.intravenous injection FRANCEC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CDMO services for FDPs segmented 
by the delivery mechanism used, i.e.intravenous injection GERMANYC6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER 
CARDIOVASCULAR PRD --> IBUPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- AUSTRIAB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- BELGIUMC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- BELGIUMC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- BELGIUMS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- BULGARIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- BULGARIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[70-80]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL!IRON METAL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
ASCORBIC ACID!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLIC88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES 
NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[60-70]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)-CZECH 
REPUBLICN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ESTONIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- FINLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- FINLANDC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> 
ACETYLCYSTEINE[20-30]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- FRANCE01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> 
ACETYLCYSTEINE[30-40]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- FRANCE01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> 
CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
SODIUM[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- FRANCE02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC 
ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> 
COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS 
HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO 
BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCE83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> 
COMPOSITION UNKNOWN[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- FRANCE87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED 
GUM&G --> COMPOSITION UNKNOWN[50-60]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- FRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEA1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> 
CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEA6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W 
ELECTRO --> MACROGOL(S)[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEA6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> 
MACROGOL(S)!POTASSIUM!SODIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- FRANCEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCEJ1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR 
TYPE --> ERYTHROMYCIN[10-20]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- FRANCE R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BENZOIC ACID!BROMINE!CODEINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC 
ACID!BROMOFORM!CODEINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCER5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> 
CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCES1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- FRANCES2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
RIFAMYCIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-
PROPANOL[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- GERMANY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-
PROPANOL[40-50]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- GERMANY03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO 
OVATA[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> 
CALCIUM!MAGNESIUM!POTASSIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC[50-60]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- GERMANY06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> 
SALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> 
LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> 
MENTHA ARVENSIS[70-80]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYA7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-
ORGANISM --> LACTOBACILLUS HELVETICUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[60-70]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- GERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYD3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING 
AGENTS --> ZINC[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- GERMANYG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [0-5]% by 
volume
CMO services (excluding CDO 
services)- GERMANYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYH2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN -
-
> DEXAMETHASONE[40-50]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- GERMANYH4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & 
SIMILAR --> OSILODROSTAT[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYK4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> 
HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> PHENYLBUTAZONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> 2-PROPANOL[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- GERMANYM3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE 
RELAXANTS,CENTRAL --> METHOCARBAMOL[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- GERMANYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[60-70]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- GERMANYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GERMANYV3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL 
PREPARATIONS --> MENTHA ARVENSIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECE06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECEC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECED1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- GREECEG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- HUNGARYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- HUNGARYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[50-60]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- HUNGARYC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- HUNGARYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- IRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- IRELANDG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> OXYBUTYNIN[30-40]% by value / [5-10]% by 
volume
CMO services (excluding CDO 
services)- ITALY01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> 
ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZETHONIUM CHLORIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!ENOXOLONE!HYALURONIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> 
DICLOFENAC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 
NAPROXEN[40-50]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- ITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> 
ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> 
TILACTASE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[70-80]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
BACILLUS COAGULANS!PYRIDOXINE!THIAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
COLECALCIFEROL!LACTOBACILLUS REUTERI[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED)[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[60-70]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALY03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC 
MEDICINES[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> 
DIMETHYL SULFONE[50-60]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- ITALY04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> 
DIMETHYL SULFONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO 
OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ARGININE[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> 
LYSINE[50-60]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALY04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> 
INOSITOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> 
HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- ITALY06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> 
NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> 
HYALURONIC ACID!SODIUM!TROMETAMOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> 
EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> 
COMPOSITION UNKNOWN[60-70]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- ITALY10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> 
PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC 
ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[50-60]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALY12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> 
DIOSCOREA VILLOSA[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALY18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> 
BORAGO OFFICINALIS[20-30]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- ITALY87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH 
--> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
DOMPERIDONE[60-70]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST 
CORTICOSTER PROD --> BUDESONIDE[20-30]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- ITALYA7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM 
BOWEL DIS PRD OTH --> CROMOGLICIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYA7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> 
DIMETICONE!LOPERAMIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYA9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES - -
> TILACTASE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYC10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA 
RED) --> LOVASTATIN[70-80]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- ITALYC1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC 
PREPS --> ALPROSTADIL ALFADEX[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYC4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB 
ACTIV --> CINNARIZINE[40-50]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- ITALYC5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-
HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> BISOPROLOL[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- ITALYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- ITALYD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[60-70]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYG4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYJ1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --
> CEFTIBUTEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYJ1D CEPHALOSPORINS & COMBS --> J1D2 
CEPHALOSPORINS,PARENT. --> CEFODIZIME[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> NAPROXEN[50-60]% by value / [40-50]% by 
volume
CMO services (excluding CDO 
services)- ITALYN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYR1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> 
BUDESONIDE[60-70]% by value / [60-70]% by 
volume (CVC share [70-80]% by 
value / [70-80]% by volume)
CMO services (excluding CDO 
services)- ITALY R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE[60-70]% by value / [50-60]% by 
volume (CVC share [60-70]% by 
value / [60-70]% by volume)
CMO services (excluding CDO 
services)- ITALYR6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES 
SYSTEMIC --> RUPATADINE[30-40]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- ITALYS1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-
ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- ITALYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYS2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> 
CIPROFLOXACIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ITALYS2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR - -
> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LATVIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LATVIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LATVIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LATVIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[40-50]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- LITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LITHUANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LITHUANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LITHUANIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[70-80]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- LITHUANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- LUXEMBOURGC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NETHERLANDSB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NETHERLANDSG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NETHERLANDSN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- NETHERLANDSS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NORWAYB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- NORWAYC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- NORWAYS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLAND01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC 
ACID!LACTOFERRIN!MENTHOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLAND10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[50-60]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- POLAND10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O 
OINTMENTS/CREAMS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLAND12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- POLANDC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[70-80]% by value / [60-70]% by 
volume
CMO services (excluding CDO 
services)- POLANDC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- POLANDG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM 
OFFICINALE[70-80]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE 
BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE 
BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES -
-> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC 
ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC 
ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> 
COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> 
COLECALCIFEROL[30-40]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALA2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> 
SUCRALFATE[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALA5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT 
LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALA6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> 
CITRIC ACID!DODECYL SULFOACETIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALC9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC 
ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> FLAVOXATE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALG4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[50-60]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S 
PLN --> DEXIBUPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALM2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & 
ANALG --> FLURBIPROFEN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALM4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT 
PREPARATIONS --> COLCHICINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGAL N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
SISYMBRIUM OFFICINALE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALR2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> 
TIBEZONIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- PORTUGALS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
INULIN!MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> 
CALCIUM!COLECALCIFEROL[30-40]% by value / [20-30]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> 
FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE + TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE 
+ TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIAC5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE 
THERAPY,SYSTEM. --> DIOSMIN[80-90]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIAD1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT 
ANTIFUNG --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIAG1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> 
METRONIDAZOLE!NEOMYCIN!NYSTATIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- ROMANIAG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG 
ANTIFUNGALS --> FENTICONAZOLE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> 
CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> 
ACETYLSALICYLIC ACID!ASCORBIC ACID[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> 
CHARCOAL + IRON METAL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> 
CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN[70-80]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> 
ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> 
LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIA10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS 
ACULEATUS!SODIUM[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAC5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O 
CORTIC --> LIDOCAINE!TRIBENOSIDE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[60-70]% by value / [30-40]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAG4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE 
PRD --> PROPIVERINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> ACETYLSALICYLIC ACID[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAN2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC 
ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SLOVAKIAS1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> 
HYALURONIC ACID!MALVA SYLVESTRIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE[70-80]% by value / [0-5]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> 
FRUCTOOLIGSACCHARIDES + MALTODEXTRIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS LACTIS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> 
LACTOBACILLUS REUTERI[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS 
SALIVARIUS[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> COMPOSITION UNKNOWN[40-50]% by value / [10-20]% by 
volume
CMO services (excluding CDO 
services)- SPAIN86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-
AERO+SPRAY --> DIMETICONE!JOJOBA OIL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAINA3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> 
CINITAPRIDE[70-80]% by value / [70-80]% by 
volume
CMO services (excluding CDO 
services)- SPAINB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAINC7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING 
AGENTS,PLAIN --> METOPROLOL[80-90]% by value / [80-90]% by 
volume
CMO services (excluding CDO 
services)- SPAINC8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR 
COMB --> FELODIPINE!METOPROLOL[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAING4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD 
OTH --> ALPROSTADIL[40-50]% by value / [50-60]% by 
volume
CMO services (excluding CDO 
services)- SPAING4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL 
PRODS --> LIDOCAINE!PRILOCAINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SPAINN5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> 
CARIPRAZINE[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SWEDENB6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH 
HAEMATOLOGIC AGENTS --> HEMIN[90-100]% by value / [90-100]% by 
volume
CMO services (excluding CDO 
services)- SWEDENS1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM 
TOPICAL --> MERCAPTAMINE[90-100]% by value / [90-100]% by 
volume
Case M.10247 - CVC/Coope r
Appendix 7.2
Upstream Hypothetical Market Segment 
(CDMO )Upstream Hypothetical Market Sub-Segment 
(CDMO )Geographic Market Share (2020, EEA) Geographic Market Product Market (ATC3/CHC3) Share (2020)
BULGARIA A11C  VIT A & D INC. COMBS [30-40]% by value / [30-40]% by volume
ITALY 04F1      CALCIUM SUPPLEMENTS [30-40]% by value / [30-40]% by volume
ROMANIA A11C  VIT A & D INC. COMBS [40-50]% by value / [40-50]% by volume
SLOVAKIA A11C  VIT A & D INC. COMBS [50-60]% by value / [50-60]% by volume
SPAIN 04F1      CALCIUM SUPPLEMENTS [80-90]% by value / [80-90]% by volume
G2F   TOPICAL SEX HORMONES [30-40]% by value / [20-30]% by volume
G3C   OESTROG EX G3A,G3E,G3F [20-30]% by value / [50-60]% by volume
SPAIN G2F   TOPICAL SEX HORMONES [30-40]% by value / [50-60]% by volume
sterile liquid pharmaceuticals LITHUANIA G3G   GONADOTROPHINS [50-60]% by value / [50-60]% by volume
CDMO services for FDPs se gmented b y the 
conditions of manufacture i esterile environment LITHUANIA G3G   GONADOTROPHINS [50-60]% by value / [50-60]% by volume
BULGARIA A11C  VIT A & D INC. COMBS [30-40]% by value / [30-40]% by volume
G2F   TOPICAL SEX HORMONES [30-40]% by value / [20-30]% by volumeG3C   OESTROG EX G3A,G3E,G3F [20-30]% by value / [50-60]% by volume
ITALY 04F1      CALCIUM SUPPLEMENTS [30-40]% by value / [30-40]% by volumePOLAND G3F   OESTROGEN + PROGESTOGEN [30-40]% by value / [30-40]% by volumeROMANIA A11C  VIT A & D INC. COMBS [40-50]% by value / [40-50]% by volumeSLOVAKIA A11C  VIT A & D INC. COMBS [50-60]% by value / [50-60]% by volume
04F1      CALCIUM SUPPLEMENTS [80-90]% by value / [80-90]% by volumeG2F   TOPICAL SEX HORMONES [30-40]% by value / [50-60]% by volume
biopharmaceutical APIs LITHUANIA G3G   GONADOTROPHINS [50-60]% by value / [50-60]% by volumeBULGARIA A11C  VIT A & D INC. COMBS [30-40]% by value / [30-40]% by volumeITALY 04F1      CALCIUM SUPPLEMENTS [30-40]% by value / [30-40]% by volumeROMANIA A11C  VIT A & D INC. COMBS [40-50]% by value / [40-50]% by volumeSLOVAKIA A11C  VIT A & D INC. COMBS [50-60]% by value / [50-60]% by volumeSPAIN 04F1      CALCIUM SUPPLEMENTS [80-90]% by value / [80-90]% by volume
G2F   TOPICAL SEX HORMONES [30-40]% by value / [20-30]% by volumeG3C   OESTROG EX G3A,G3E,G3F [20-30]% by value / [50-60]% by volume
POLAND G3F   OESTROGEN + PROGESTOGEN [30-40]% by value / [30-40]% by volumeSPAIN G2F   TOPICAL SEX HORMONES [30-40]% by value / [50-60]% by volume(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) 
At least EEA-wide <10%CDMO services for FDPs segmented by the type 
of API used, i.e.chemically-synthesized APIsFRANCE
SPAIN
CDMO services for FDPs segmented by the 
delivery mechanism used, i.e.swallowing
absorption through the skinFRANCECDMO services for FDPs segmented by its 
pharmaceutical form, i.e.solid and powder pharmaceuticals
liquid and semi-solid pharmaceuticalsFRANCEUpstream Market (Target) Downstream FDP Market (Theramex)
Case M.10247 - CVC/Coope r
Appendix 7.2
Upstream Hypothetical Market Segment 
(CDMO )Upstream Hypothetical Market Sub-Segment 
(CDMO )Geographic Market Share (2020, EEA) Geographic Market Product Market (ATC4/CHC4) Share (2020)
BELGIUM G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
FINLAND G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
04F1E EFFERVESCENT [90-100]% by value / [90-100]% by volumeG3A1 MONOPHAS PREP<50MCG OEST [20-30]% by value / [30-40]% by volumeG3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
GERMANY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeITALY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeLITHUANIA G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeLUXEMBOURG G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumePORTUGAL G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSPAIN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSWEDEN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeBELGIUM G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeFINLAND G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
04F1E EFFERVESCENT [90-100]% by value / [90-100]% by volumeG3A1 MONOPHAS PREP<50MCG OEST [20-30]% by value / [30-40]% by volumeG3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
GERMANY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeITALY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeLITHUANIA G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeLUXEMBOURG G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumePORTUGAL G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSPAIN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSWEDEN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeBELGIUM G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeFINLAND G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
04F1E EFFERVESCENT [90-100]% by value / [90-100]% by volumeG3A1 MONOPHAS PREP<50MCG OEST [20-30]% by value / [30-40]% by volumeG3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
GERMANY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) 
FRANCE
FRANCE FRANCEUpstream Market (Target) Downstream FDP Market (Theramex)
At least EEA-wide <10%CDMO services for FDPs segmented by its 
pharmaceutical form, i.e.
CDMO services for FDPs segmented by the type 
of API used, i.e.
CDMO services for FDPs segmented by the 
swallowingchemically-synthesized APIssolid and powder pharmaceuticals
ITALY G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volume
LITHUANIA G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeLUXEMBOURG G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumePORTUGAL G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSPAIN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumeSWEDEN G3A2 MONOPHAS PREP>=50MCG OES [90-100]% by value / [90-100]% by volumedelivery mechanism used, i.e.
swallowing
Case M.10247 - CVC/Cooper
Appendix 7.2
Upstream Hypothetical Market Segment (CDMO)Upstream Hypothetical Market Sub Segmen  
(CDMO )Geographic Market Share (2020, EEA)Geographic 
MarketProduct Market (Molecule) Share (2020)
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [60-70]% by value / [60-70]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [50-60]% by value / [40-50]% by volume
FINLAND G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE [90-100]% by value / [90-100]% by volumeA12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID [90-100]% by value / [90-100]% by volume
D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE [90-100]% by value / [90-100]% by volumeG1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL [40-50]% by value / [30-40]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeM1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN [80-90]% by value / [80-90]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [20-30]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [10-20]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeG3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volumeG3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID[40-50]% by value / [20-30]% by volume 
(CVC share [40-50]% by value / [20-30]% 
LITHUANIA G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeG3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [90-100]% by value / [90-100]% by volume04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID [90-100]% by value / [90-100]% by volumeA11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL [40-50]% by value / [40-50]% by volumeA12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
POLAND G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL [90-100]% by value / [90-100]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeG3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [10-20]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [70-80]% by value / [70-80]% by volume
SWEDEN G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL [20-30]% by value / [50-60]% by volumeBELGIUM
FRANCE
GERMANY
ITALY
LUXEMBOURG
NETHERLANDS
PORTUGAL
SPAIN
FRANCEDownstream FDP Market (Theramex)(Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) 
CDMO services for FDPs segmented by its pharmaceutical form, i.e.solid and powder pharmaceuticals
liquid and semi-solid pharmaceuticalsUpstream Market (Target)
ITALY G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
LATVIA G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
PORTUGAL G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
SPAIN G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
GERMANY 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN [0-5]% by value / [40-50]% by volume
HUNGARY G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA [40-50]% by value / [20-30]% by volume
GERMANY 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN [0-5]% by value / [40-50]% by volume
HUNGARY G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA [40-50]% by value / [20-30]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [60-70]% by value / [60-70]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [50-60]% by value / [40-50]% by volume
FINLAND G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume
06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID [90-100]% by value / [90-100]% by volume
D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL [40-50]% by value / [30-40]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL [20-30]% by value / [50-60]% by volume
G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volume
M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN [80-90]% by value / [80-90]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [20-30]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [10-20]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volume
G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volume
G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID[40-50]% by value / [20-30]% by volume 
(CVC share [40-50]% by value / [20-30]% 
LATVIA G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
LITHUANIA G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID [90-100]% by value / [90-100]% by volume
A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL [40-50]% by value / [40-50]% by volume
A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
POLAND G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL [90-100]% by value / [90-100]% by volumeBELGIUM
FRANCE
GERMANY
ITALY
LUXEMBOURG
NETHERLANDSAt least EEA-wide <[10-20]%sterile liquid pharmaceuticals
CDMO services for FDPs segmented by the conditions of manufacture, i.e. sterile environment
CDMO services for FDPs segmented by the type of API used, i.e.chemically-synthesized APIs
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [10-20]% by volume
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [70-80]% by value / [70-80]% by volume
SWEDEN G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
GERMANY 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN [0-5]% by value / [40-50]% by volume
HUNGARY G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA [40-50]% by value / [20-30]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [60-70]% by value / [60-70]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [50-60]% by value / [40-50]% by volume
FINLAND G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume
A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL [40-50]% by value / [30-40]% by volumeG3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN [80-90]% by value / [80-90]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [20-30]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [10-20]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volume
G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID[40-50]% by value / [20-30]% by volume 
(CVC share [40-50]% by value / [20-30]% 
LITHUANIA G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [80-90]% by value / [80-90]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID [90-100]% by value / [90-100]% by volumeM5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [90-100]% by value / [90-100]% by volume
04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID [90-100]% by value / [90-100]% by volume
A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL [40-50]% by value / [40-50]% by volume
A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
POLAND G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL [90-100]% by value / [90-100]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [30-40]% by value / [10-20]% by volume
G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID [70-80]% by value / [70-80]% by volume
SWEDEN G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE [90-100]% by value / [90-100]% by volume
06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume
G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE [90-100]% by value / [90-100]% by volume FRANCEFRANCE
GERMANY
ITALY
LUXEMBOURG
NETHERLANDSPORTUGAL
SPAIN
BELGIUM
PORTUGAL
SPAINbiopharmaceutical APIs
CDMO services for FDPs segmented by the delivery mechanism used, i.e.swallowing
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volume
G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL [20-30]% by value / [50-60]% by volumeG3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volu me
G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volumeG3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL [90-100]% by value / [90-100]% by volu me
LATVIA G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volumePORTUGAL G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volumeSPAIN G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE [90-100]% by value / [90-100]% by volumeITALYabsorption through the skin